Identification of novel genetic alterations in pediatric cytogenetically normal acute myeloid leukemia by next-generation sequencing by Togni, Marco
 
 
Alma Mater Studiorum – Università di Bologna 
 
 
 
 
DOTTORATO DI RICERCA IN 
 
ONCOLOGIA E PATOLOGIA SPERIMENTALE 
 
Ciclo XXVII 
 
Settore Concorsuale di afferenza: 06/G1 
 
Settore Scientifico disciplinare: MED/38 
 
 
 
 
IDENTIFICATION OF NOVEL GENETIC ALTERATIONS IN 
PEDIATRIC CYTOGENETICALLY NORMAL ACUTE MYELOID 
LEUKEMIA BY NEXT-GENERATION SEQUENCING 
 
 
Presentata da: 
Marco Togni 
 
 
 
 
 
Coordinatore Dottorato Relatore 
Chiar.mo Prof. Pier Luigi Lollini  Chiar.mo Prof. Andrea Pession 
 
 
 
 
 
 
Esame Finale Anno 2015
I 
 
 
TABLE OF CONTENT 
LIST OF FIGURES......................................................................................................................V 
LIST OF TABLES.....................................................................................................................VII 
ABSTRACT..............................................................................................................................VIII 
CHAPTER I – Introduction..........................................................................................................1 
1.1 Pediatric acute myeloid leukemia……………………………………………………………..1 
1.1.1 Epidemiology and overall outcome…………………………………………………………1 
1.1.2 Etiopathogenesis……………………………………………………………………………1 
1.1.3. Classification………………………………………………………………………………3 
1.1.4 Molecular Pathogenesis……………………………………………………………………..5 
1.1.4.1 Proliferation and/or pro-survival alterations in AML (Class I) …………………………..5 
FLT3 activating mutations………………………………………………………………………...5 
c-KIT activating mutations………………………………………………………………………..6 
RAS activating mutations………………………………………………………………………...6 
PTPN11 activating mutations……………………………………………………………………..8 
NPM1 activating mutations……………………………………………………………………….8 
Janus kinase 2 (JAK2) activation mutations………………………………………………………9 
1.1.4.2 Genetic lesions impairing the myeloid differentiation (Class II) …………………………9 
Core-binding factor (CBF) alterations…………………………………………………………9 
II 
 
CCAAT/enhancer binding protein α (C/EBPα) loss of function mutations……………………...10 
PML/RARα and acute promyelocytic leukemia………………………………………………….10 
Mixed lineage leukemia (MLL) gene alterations………………………………………………...12 
OTT/MAL and acute megakaryoblastic leukemia………………………………………………..13 
1.1.5 Prognostic markers and risk stratification………………………………………………….14 
Therapy response and MRD monitoring…………………………………………………………14 
1.2 Mutational landscape of cytogenetically normal acute myeloid leukemia (CN-AML) as 
drawn by next-generation sequencing, state of art……………………………………………….17 
1.2.1 The modern genomic era and AML gene discovery……………………………………….18 
1.2.1.1  Re-defying the molecular profile of adult AML………………………………………...18 
1.2.1.1  The landscape of genetic alterations in childhood AML………………………………..20 
AIM...............................................................................................................................................24 
CHAPTER II – Study design and Methods...............................................................................25 
2.1 Patients………………………………………………………………………………………25 
2.2 Whole-transcriptome sequencing…………………………………………………………….25 
2.2.1 RNA-seq libraries preparation……………………………………………………………..25 
2.2.2 RNA-seq libraries validation and quantification…………………………………………..27 
2.2.3 Bridge-Amplification and sequencing on HiScanSQ (Illumina) ………………………….27 
2.3 Bioinformatic analysis……………………………………………………………………….27 
2.4 RNA isolation, RT-PCR and Sanger sequencing……………………………………………28 
2.5 Gene expression analysis from RNA-seq data……………………………………………….29 
III 
 
2.7 Quantitative (q) PCR for USP42 and PRDM16 genes……………………………………….30 
2.8 Fluorescence in situ hybridization (FISH) …………………………………………………..30 
2.9 Cloning and retroviral transduction of TNIP1-PDGFRB fusion…………………………….31 
2.10 In-vitro functional analyses for TNIP1-PDGFRB fusion…………………………………..31 
2.10.1 Cytokine-independent assay……………………………………………………………...31 
2.10.2 Cytokine-independent assay……………………………………………………………...31 
CHAPTER III – Results and Discussion……………………………………………………...32 
3.1 Gene fusions are a hallmark of pediatric CN-AML………………………………………….32 
3.2 Identification of CBFA2T3-GLIS2 fusion transcript in children with CN-AML……………33 
3.2.1 CBFA2T3-GLIS2 is recurrent in pediatric CN-AML………………………………………33 
3.2.2 CBFA2T3-GLIS2 identifies a subset of childhood CN-AML with poor outcome…………36 
3.3 Identification of a novel DHH-RHEBL1 fusion transcript in pediatric CBFA2T3-GLIS2-
positive AML patients……………………………………………………………………………37 
3.3.1 DHH-RHEBL1 fusion transcript is recurrent in pediatric CBFA2T3-GLIS2-positive 
AML……………………………………………………………………………………………38 
3.3.2 DHH-RHEBL1–positive patients exhibit a specific gene expression signature and an 
overexpression of both DHH and RHEBL1………………………………………………...........40 
3.4 Identification of RUNX1-USP42 and PRDM16-SKI fusion transcripts……………………42 
3.5 NUP98-PHF23 is a recurrent fusion gene in pediatric CN-AML…………………………..46 
3.6 Identification of TNIP1-PDGFRB fusion transcript in children with CN-AML……………52 
3.6.1 TNIP1-PDGFRB sustains cytokine-independent growth in-vitro………………………....52 
3.6.2 Ba/F3 cells expressing TNIP1-PDGFRB are sensitive to treatment with TKIs…………...52 
IV 
 
CHAPTER IV – Conclusions and future directions……………………………………….....55 
LIST OF PAPERS………………………………………………………………………….......58 
REFERENCES…………………………………………………………………………………59 
ACKNOWLEDGEMENTS……………………………………………………………………70 
 
 
 
 
 
 
 
 
 
V 
 
 
LIST OF FIGURES 
Figure 1. Incidence of acute myeloid leukemia (AML) by age......................................................2 
Figure 2. Schematic illustrating the structure and function of FLT3, including the sites of the 
most common activating mutations........................................................... .....................................7 
Figure 3. CBF complex genes rearrangements in acute myeloid leukemia (AML) ....................11 
Figure 4. Distribution of major MLL fusion partner genes in de-novo childhood and adult 
leukemias.......................................................................................................................................12 
Figure 5. Schematic representation of the MLL protein and MLL fusions..................................13 
Figure 6. Newly devised risk stratification for AML....................................................................15 
Figure 7. Karyotypic alterations in both pediatric and adult AML...............................................17 
Figure 8. Complementation groups of genetic changes in AML..................................................19 
Figure 9. Characterization of mutations in adul AML..................................................................20 
Figure 10. AML gene fusions.......................................................................................................21 
Figure 11. Somatic mutations in adults and childhood AML......................................................23 
Figure 12. Age-based somatic mutations groups in adults and childhood AML..........................23 
Figure 13. Most significant fusion genes identified by RNA-seq in a pediatric cohort of 19 CN-
AML patients.................................................................................................................................34 
Figure 14. CBFA2T3-GLIS2 fusion transcript is a novel common feature of pediatric CN-AML, 
predicting poorer outcome.............................................................................................................35 
Figure 15. DHH-RHEBL1 is a novel fusion transcript recurrent in pediatric CBFA2T3-GLIS2 
positive AML.................................................................................................................................39 
VI 
 
Figure 16. Implications of DHH-RHEBL1 fusion transcript expression......................................39 
Figure 17. Analysis of gene expression profile of DHH-RHEBL1-positive patients. .................41 
Figure 18. RUNX1-USP42 and PRDM16-SKI fusion identified through RNA-seq in a child with 
acute myeloid leukaemia (AML) and del(5q) ...............................................................................43 
Figure 19. Identification of NUP98-PHF23 in pediatric CN-AML.............................................48 
Figure 20. Identification of TNIP1-PDGFRB in pediatric CN-AML...........................................52 
Figure 21. TNIP1-PDGFRB sustains cytokine-independent growth in-vitro...............................53 
Figure 22. Ba/F3 cells expressing TNIP1-PDGFRB are sensitive to treatment with TKIs……..54 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII 
 
 
LIST OF TABLES 
Table 1. French-America-British (FAB) classification for AML...................................................3 
Table 2. The World Health Organization (WHO) classification of acute myeloid leukemia…….4 
Table 3. Genetic lesions in pediatric acute myeloid leukemia......................................................16 
Table 4. Clinical characteristics of the 19 AML patients analyzed by RNA-seq.........................26 
Table 5. List of the primers used for RT-PCR and Sanger sequencing........................................28 
Table 6. Gene fusion identified by RNA-seq in pediatric CN-AML............................................33 
Table 7. Clinical features of the CN-AML patients harboring the CBFA2T3-GLIS2 fusion 
gene................................................................................................................................................36 
Table 8. Main characteristics of t(7;21)(p22; q22) positive patients............................................46 
Table 9. Clinical features of pediatric CN-AML patients harboring the NUP98-PHF23 fusion 
gene................................................................................................................................................49 
Table 10. PDGFRB-fusions so far reported in myeloid malignancies..........................................51 
 
 
 
 
 
 
 
VIII 
 
 
ABSTRACT 
  
Pediatric acute myeloid leukemia (AML) is a molecularly heterogeneous disease that 
arises from genetic alterations in pathways that regulate self-renewal and myeloid differentiation. 
While the majority of patients carry recurrent chromosomal translocations, almost 20% of 
childhood AML do not show any recognizable cytogenetic alteration and are defined as 
cytogenetically normal (CN)-AML. CN-AML patients have always showed a great variability in 
response to therapy and overall outcome, underlining the presence of unknown genetic changes, 
not detectable by conventional analyses, but relevant for pathogenesis, dynamics, and outcome 
of AML. 
During the last decade, the development of novel genome-wide techniques such as next-
generation sequencing (NGS), have tremendously improved our ability to interrogate the cancer 
genome, raising, for the first time, the possibility to have a complete picture of all the genetic 
alterations that could be present in a cancer cell. With the aim of investigating the mutational 
landscape of CN-AML, lately, several studies have taken advantage of the novel NGS 
technologies, and novel important insights in the molecular pathogenesis of CN-AML have been 
achieved, especially in adults. Despite that, mutations find to be recurrent in adult AML appear 
to be rare or absent in childhood AML, straighten the significant differences between AML in 
elderly and young patients. Based on this background, the overall aim of this research study was 
to investigate the mutational landscape of pediatric CN-AML patients negative for all the 
currently known somatic mutations reported in AML through whole-transcriptome sequencing 
(RNA-seq). 
RNA-seq performed on diagnostic leukemic blasts from 19 pediatric CN-AML cases 
revealed a considerable incidence of cryptic chromosomal rearrangements in this type of 
leukemia, with the identification of 21 putative fusion genes. Moreover, and more importantly, 
several of the fusion genes that were identified in this study are recurrent and might have a 
prognostic and/or therapeutic relevance. A paradigm of that is the CBFA2T3-GLIS2 fusion, 
which has been demonstrated to be a novel common (8.4%) alteration in pediatric CN-AML, 
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predicting poor outcome. Noteworthy, due to its prognostic relevance, the presence of this fusion 
gene will be included in the stratification of patients in the new AIEOP LAM 2012/01 Italian 
clinical trial. 
Beside the role of this fusion gene in defying the outcome of pediatric CN-AML patients, 
important findings have been obtained in the identification of novel molecular alterations that 
can be therapeutically targeted for more effective treatment strategies. Within the epigenetic 
regulators,  the identification of NUP98-JARID1A (1.2%), and NUP98-PHF23 (2.4%) fusions 
suggest the use of disulfiram (Food and Drug Administration-approved drug) or other small 
molecules that inhibit the binding of the plant homology domain to histone 3 trimehylated-lysine 
4 and preliminary functional results support this strategy. Alterations activating tyrosine kinases, 
such as the fusion TNIP1-PDGFRB identified in one CN-AML case support the use of already 
approved and widely used tyrosine kinase inhibitors (e.g. imatinib, dasatinib) to specifically 
inhibit leukemia cells. This hypothesis has been investigated and confirmed in in vitro studies 
providing a strong rational for subsequent in vivo investigations. In conclusion, this study 
provides new insights in the knowledge of genetic alterations underlying pediatric AML, defines 
novel prognostic markers and putative therapeutic targets, and prospectively ensures a correct 
risk stratification and risk-adapted therapy also for the “all-neg” AML subgroup.  
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CHAPTER I – Introduction 
1.1 Pediatric acute myeloid leukemia 
Acute myeloid leukemia (AML) is a group of genetically heterogeneous hematopoietic disorders 
of the myeloid lineage characterized by the uncontrolled growth and clonal expansion without 
complete differentiation of a hematopoietic/stem progenitor1. 
1.1.1 Epidemiology and overall outcome 
In the pediatric setting, AML accounts for approximately 20% of leukemias with seven newly 
diagnosed children and adolescents (< 19 years-old) out of one million of patients in Italy, 
annually2. Overall, the incidence is slightly higher in male (7.4/million cases in male compared 
to 6.5/million in female) with a peak in both genders under 1 year of life (infant-AML) 2,3 
(Figure 1). In the last two decades, the prognosis of pediatric AML has been significantly 
improved4,5. In the 1970s, the survival rates of children younger than 20 years with a newly 
diagnosed AML was lover than 20%.6 Nowadays, according to the AIEOP AML2002/01 trial 
and other international studies, the probability of 8-years event-free-survival (EFS) is 
approximately up to 50-70%7–13. Different factors contributed to this remarkable result, 
including: i) use of more effective anti-leukemic agents, such as cytarabine and anthracyclines, 
ii) better risk-group stratification based on cytogenetic and molecular analysis, iii) optimization 
in induction therapy and improvements in post remission/supportive treatment, and more 
importantly, iv) the broad use of allogeneic (ALLO) hematopoietic stem cell transplantation 
(HSCT) in high-risk (HR) patients12,14. 
1.1.2 Etiopathogenesis 
Currently, AML is broadly classified into two main categories: de-novo AML and secondary 
AML. While a de-novo AML develops without any exposure to known risk factors and the cause 
of development remains not known, the rise of a secondary AML is subsequent to a prior 
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exposure to cytotoxic agents, or antecedent hematopoietic insufficiency (myelodysplastic 
syndrome [MDS], marrow failure, etc…)15. Exposure to high dose radiation, chemical 
compounds (benzene, herbicides, pesticides), and commonly used antitumor chemotherapy drugs 
such as alkylating agents, platinum (including cyclophosphamide, mechlorethamine, 
procarbazine, chlorambucil, melphalan, busulfan, carmustine, cisplatin, and carboplatin) and 
treatment with topoisomerases II inhibitors (etoposide) have been linked to an increased risk of 
AML (therapy-related AML, tAML) 16–18. Additionally, higher risk to develop AML is 
associated with several congenital syndromes. Among them, the Down syndrome increase the 
probability to develop AML (particularly the FAB M7 subtype) of 20-fold compared to a 
pediatric healthy population, even if  the leukemia often undergoes to a spontaneous resolution19. 
The Shwachman-Diamond syndrome20, Kostmann syndrome (severe congenital neutropenia)21 
and the Fanconi anemia22 are other conditions associated with an increased  risk to develop AML 
in pediatrics. 
 
Figure 1. Incidence of acute myeloid leukemia (AML) by age. From Tarlock K, Meshinchi S. Pediatric 
Acute Myeloid Leukemia: Biology and Therapeutic Implications of Genomic Variants. Pediatr Clin North 
Am. 2015 Feb;62(1):75-93. 
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1.1.3. Classification 
Historically, the first reliable and systemic attempt of a uniform system for classification and 
nomenclature of AML was provided by the French-American-British (FAB) classification23,24. 
This classification system was based on the morphological and histological characteristics of the 
leukemic cells and divide the AML by the predominant lineage and stage of differentiation of the 
leukemic blasts24 (Table 1) . Although the FAB classification remains useful and commonly used 
nowadays for an overall description of myoblasts morphology, non-random recurrent cytogenetic 
and/or molecular abnormalities that are well-known to have a prognostic value in AML (Table 3) 
are not considered in this classification system. Thus, the need of considering the prognostic 
importance of these cytogenetic and/or molecular lesions has provided the major reason to the 
design of a novel AML classification in which these parameters are taken into account. The most 
recent World Health Organization (WHO) AML classification system is based on the systematic 
delineation of distinct clinical pathologic entities in which are take in account several parameters 
including morphology, cell surface, cytogenetic and/or molecular markers of the leukemic cells25 
(Table 2) . 
 
Table 1. French-America-British (FAB) classification for AML 
M0 AMLwith no Romanowsky or cytochemical evidence of differentiation 
M1 Myeloblastic leukemia with litter maturation 
M2 Myeloblastic leukemia with maturation 
M3 Acute promyelocytic  leukemia 
M3h Acute promyelocytic  leukemia, hypergranular variant 
M3v Acute promyelocytic  leukemia, microgranular variant 
M4 Actue myelomonocytic leukemia 
M4eo Actue myelomonocytic leukemia with dysplastic marrow meosinophils 
M5 Acute monoblastic leukemia 
M5a Acute monoblastic leukemia, poorly differentiated 
M5b Acute monoblastic leukemia, differentiated 
M6 Erytroleukemia 
M7 Acute megakaryoblastic leukemia 
Modified from Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. 
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative 
group. Br J Haematol. 1976 Aug;33(4):451-8. 
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Table 2. The World Health Organization (WHO) classification of acute myeloid leukemia 
Acute myeloid leukemia with recurrent genetic abnormalities 
AML with balanced translocations/inversions 
Acute myeloid leukemia with t(8;21)(q22;q22); AML/ETO 
Acute myeloid leukemia with inv(16)(p13;q22) or t(16;16)(p13;q22); CBFB/MYH11 
Acute myeloid leukemia with t(15;17)(q22;q21); PML/RARα 
Acute myeloid leukemia with t(9;11)(p22;q23); MLL/AF9 
Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); OTT/MAL 
Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)( q21;q26.2); RPN1/EVL1 
Acute myeloid leukemia with t(6;9)(p23;q34); DEK/NUP124 
AML with gene mutations 
Mutation affecting FLT3, NPM1, C/EBPα, KIT, MLL, WT1, NRAS and KRAS 
Acute myeloid leukemia with myelodisplasia-related changes 
Acute leukemia with 20% or more peripheral blood or bone marrow blasts with morphological features of 
myelodysplasia or a prior history of a myelodyplastic syndrome (MDS) or myelodyplastyic/myeloproliferative 
neoplasm (MDS/MPN), or MDS-related cytogenetic abnormalities, and absence of the specific genetic 
abnormalities of AML. 
Therapy-related myeloid neoplasms 
Therapy-related acute myeloid leukemia (tAML), myelodysplastic syndrome (tMDS), and 
myelodyplastyic/myeloproliferative neoplasm (tMDS/MPN) occurring as late complications of cytotoxic 
chemotherapy and/or radiation therapy administered for a prior neoplastic or non-neoplastic disorder. 
Acute myeloid leukemia, not otherwise specified 
FAB classification (M0, M1, M2, M3, M3h, M3v, M4, M4eo, M5, M5a, M5b, M6, M7. 
Myeloid sarcoma 
Tumor mass consisting of myeloid blasts with/without maturation, occurring at an anatomical site other than the 
bone marrow. 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Clinically aggressive tumor derived from the precursors of plasmacytoid dendritic cells, with a high frequency of 
cutaneous and bone marrow involvement and leukemic dissemination. 
Modified from the Vardiman JW et al. The 2008 revision of the World Health Organization (WHO) 
classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 
Jul 30;114(5):937-51. 
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1.1.4 Molecular Pathogenesis 
AML is characterized by uncontrolled cells growth and stop of differentiation of an 
hematopoietic stem precursor.1 Despite the heterogeneous pattern of genetic lesions at the base 
of the development of AML, several evidences reported in literature over the years sustain a 
shared “two-hits” model in which the leukemia arises from the cooperation between two 
different classes of genetic alterations: those that confer a proliferative and/or survival advantage 
to hematopoietic progenitors, and those that impair hematopoietic differentiation and confer 
properties of self-renewal to the hematopoietic cell at a particular stage of differentiation26. 
1.1.4.1 Proliferation and/or pro-survival alterations in AML (Class I) 
Typically, mutations belonging to this class of genetic lesions occur in genes coding for proteins 
involved in signaling pathways and in the transduction of extracellular cell proliferation signals, 
such as FLT3, c-KIT, RAS, PTPN11, NF1 genes26. 
FLT3 activating mutations 
Located on human chromosome 13 and coding for a type III tyrosine kinase receptor (TKR), 
FMS-like tyrosine kinase 3 (FLT3) gene is the most recurrent mutated gene in AML, with up to 
30% - 35% of AML patients carrying an activation mutation in this genetic locus.27 
Physiologically, the function of FLT3 receptor is strictly regulated and the activation of his 
signaling pathways is crucial for the proliferation of hematopoietic stem cells. However, in 
AML, two different types of mutations could occur, leading to the coding of a receptor 
constitutively activated that sustains an aberrant proliferation27. The most common (20% - 25% 
of cases) lesion consists in internal tandem duplications (ITD) in the juxtamembrane domain of 
FLT3 receptor ranging in size from several to > 50 amino acids. These mutations are always in 
frame, occur exclusively within a tyrosine-kinase inhibitory loop (27-ammino acid stretch) and 
are all predicted to destroy the inhibitory function of this domain, resulting in a subsequent 
constitutive activation of the tyrosine kinase domain localized in the C-termini of the receptor in 
the cytosol28. In addition to ITD, single nucleotide mutations leading to missense ammino acid 
changes or small InDels have been reported in the activation loop of FLT3 in about 5% - 10% of 
AML cases29. Likewise the ITD, these mutations in the tyrosine kinase activation loop lead to the 
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constitutive activation of the receptor (Figure 2) . Interestingly, examples of both ITD and 
activation loop mutations in the same allele of FLT3 have been reported, suggesting that the 
combination of mutations may hyperactivate the kinase and provide added proliferative 
advantage to cells that harbor both mutations26. Expression of FLT3-ITDs in pre-B murine IL3-
dependent Ba/F3 cells has been demonstrated to activate several signal transduction pathways 
known to confer proliferative and/or survival advantage, including the RAS/ MAPK, STAT, and 
PI3K/AKT pathways, and are sufficient to confer cytokine independent growth30,31. Most studies 
reported that alteration of the FLT3 gene are particularly recurrent in AML FAB M3v (acute 
promyelocytic leukemia, microgranular variant) and in  patient with a normal karyotype.32 More 
important, activating mutations in FLT3 gene are well known to be associated with a poor 
prognosis and relapse in AML, although they pave the way to the broad use of novel tyrosine-
kinase inhibitor (TKIs) that can specifically block the constitutive activation of this receptor33. 
c-KIT activating mutations 
c-KIT is a proto-oncogene located on human chromosome 4, encoding for a type III TKR. Upon 
stimulation by stem cell factor, KIT undergoes to dimerization and consequential 
transphosphorylation and activation of a downstream signaling pathways leading to proliferation, 
differentiation, and survival of hematopoietic stem cells. Ligand independent activation of KIT is 
driven by mutations that could occur in the extracellular domain of the receptor, in 
transmembrane/juxtamembrane domain and in the activation loop of the tyrosine kinase domain. 
Although the incidence of KIT activating mutations is relevant in adult patients with CBF-AML (up 
to 48%)34  and associate with a worst prognosis, the recurrence of these lesion in the pediatric setting 
seems to be lower (up to 19% of CBF-AML)35 and not associated with poor prognosis, even if 
further studies with larger cohort are required for fully assess the prognostic power of KIT mutations 
in pediatric AML and the possible therapeutic relevance as target for TKIs35. 
RAS activating mutations 
RAS oncogenes encode for a family of guanine nucleotide-binding proteins that regulate signal 
transduction on binding to a variety of membrane receptors, including c-KIT and FLT3, and 
mutations in these proteins are extremely recurrent in a large variety of human cancer, including 
leukemias. Typically the mutations consist in one single base change in codons 12, 13 or 61, 
which abrogate intrinsic RAS GTPase activity and confer constitutive activation of RAS proteins 
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and downstream effectors, such as RAF and MAPK/ERK kinases. Approximately 10–15 and 5% 
of all AML patients carry mutations in N-RAS and K-RAS, respectively36. No significant 
difference in recurrence of these mutations have been reported according to age, gender, 
diagnosis leukocytosis, type of AML (de-novo or t-AML); although an increase incidence is 
recorded in AML with inv(16)/t(16;16) and inv(3)/t(3;3) (up to 35%).36 Interestingly, only 2% of 
FLT-ITD-positive AML patients have been found positive also for RAS mutations supporting 
the “two-hit” model of AML pathogenesis. However, likewise in other human neoplasms, RAS 
activating mutations are not considered as primary event in the leukemogenesis, and is broadly 
diffuse the idea that these mutations occur later in de leukemic cells probably due to genome 
instability36. 
 
Figure 2. Schematic illustrating the structure and function of FLT3, including the sites of the most 
common activating mutations. From Annesley CE, Brown P. The Biology and Targeting of FLT3 in 
Pediatric Leukemia. Front Oncol. 2014 Sep 23;4:263. 
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PTPN11 activating mutations 
Protein tyrosine standard phosphatase non-receptor 11 (PTPN11) gene is located on chromosome 
12 and encodes a cytoplasmic protein tyrosine phosphatase (PTP) called SHP-2. SHP-2 participates 
in signal transduction downstream of growth factor, cytokines (KIT-ligand, IL3, IL6, granulocyte-
macrophage colony-stimulating factor (GM- CSF) and EPO), hormones, and cell adhesion 
molecules. It have an important role in the RAS signaling pathway and it is highly expressed in 
hematopoietic.37 Germ-line mutations in PTPN11 have been reported in an autosomal dominant 
disorder characterized by facial dysmorphy, skeletal malformations, an broad spectrum of heart 
defects (Noonan’s syndrome) 38. Moreover, Somatic mutations in PTPN11 are found in about 35% of 
juvenile myelomonocytic leukemia (JMML) cases37. Approximately 4.4% (31/702) of pediatric 
AML cases show PTPN11 mutations and the 22% of these carry also mutation in FLT3 and RAS 
genes39. In adults the frequency seems to be lower since only 2.6% (9/340) 37. No significant 
prognostic relevance has been so far established for mutation in PTPN11 gene in pediatric or adult 
AML39. 
NPM1 activating mutations 
Recurrent mutations have been reported also in the nucleolar phospho-protein B23 (NPM1) gene in 
both pediatric and adult AML, with a incidence of 5% - 10% and 35%, respectively40. NPM1 is a 
ubiquitously expressed nucleolar phosphoprotein that continuously shuttles between the nucleus and 
cytoplasm with predominant nucleolar localization. It is involved in the prevention of protein 
aggregation in the nucleolus and regulates the assembly and transport of pre-ribosomal particles 
through the nuclear membrane and DNA polymerase activity. Moreover, NPM1 is known to have a 
role in cell cycle progression, response to stress and oncogenic stimuli and regulation of the alternate 
reading frame protein (ARF)-p53 tumor suppressor pathway41. The mutations of NPM1 typically 
destroy the ability to shuttle from the cytosol to the nucleolus with a constitutive retention of NPM1 
in the first, which can easily be detected by immunohistochemistry. The cytoplasmic localization of 
NPM1 mutated protein is probably critical for its putative role in leukemogenesis36. NPM1 mutations 
are significantly associated with both pediatric and adult cytogenetically normal AML (CN-AML) 
(35% and up to 60%, respectively)40 and with FLT3- ITD, FLT3-TKD mutations. Conversely, 
decreased prevalence of NPM1 mutations is detected in presence of CEBPA mutations and MLL-
partial tandem duplication (PTD). Prognostically, CN-AML patients carrying NPM1-mutated/FLT3-
ITD negative have a significantly better response to induction therapy, better EFS and better overall-
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survival (OS) than those without NPM1 mutation, although the presence of also FLT3 mutations 
predicts for a worst outcome42 . 
Janus kinase 2 (JAK2) activation mutations 
Playing a key role in signal transduction initiated by multiple growth factor-receptors (type II 
TKR, such as erythropoietin receptor [EPOR], thrombopoietin receptor [TPOR], etc…) and 
cytokines, Janus Kinase 2 (JAK2) is a cytoplasmic tyrosine kinase with a crucial role in 
hematopoiesis43. The recurrent JAK2 V617F mutation causes replacement of a key valine 
residue leading to a constitutive activation of this kinase and the consequence hyperactivation of 
downstream signaling components, STAT5, PI3K/Akt, ERKs. Over  90% of polycythemia vera 
(PV) cases,  50% of essential thrombocythemia (ET), and in about 70% of patients with AML 
secondary to other myeloproliferative disorders show the JAK2 V617F mutation, although, 
conversely, it is a rare event (1.6%) in de-novo AML.36,44–46 
1.1.4.2 Genetic lesions impairing the myeloid differentiation (Class II) 
Accordingly to the “two-hits” model for leukemogenesis, mutations conferring pro-
survival/proliferative advantage need to be associated with mutations that impair the ability to 
differentiate of the hematopoietic progenitors for a complete outset of acute myeloid leukemia. 
Belonging to this class of lesion, chromosomal translocations (as well as inversion, duplication 
and loss of whole chromosomes) affecting genes coding for transcriptional regulators, 
components of the transcriptional activation complex, and chromatin modifiers are an hallmark 
of pediatric AML with over the 75% patients showing these alterations at diagnosis47,48. 
Core-binding factor (CBF) alterations 
The core-binding factor (CBF) is a heterodimeric transcription factor crucial for myeloid 
differentiation, and it has been demonstrated that both the component of this complex (coded by 
AML1 and CBF genes), are essential for normal hematopoiesis49. Indeed, disruptions of the 
AML1/CBF complex could cause stop of myeloid differentiation and subsequent leukemic 
transformation. Recurrent and multiple chromosomal translocations as well as non-sense/frame-
shift mutations and duplications affecting the AML1 (also known as RUNX1) and CBF genes 
have been described in AML. The most frequent chromosomal alterations involving these two 
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genes are the t(8;21) (generating the fusion protein AML1/ETO) and the inv(16)/t(16;16) 
(generating the fusion protein CBFB/SMMHC) which are present in approximately 10% and 5% 
of AML patients, respectively50.  Although through two different mechanisms, the result of these 
fusions proteins is the creation of an inactive CBF complex who is not able to start the 
transcription of important genes target required for the myeloid differentiation50 (Figure 3). 
Moreover, the AML1 gene is also involved in another translocation t(16;21) in which it results to 
be in-frame fused with the gene CBFA2T3 localized on chromosome 16. Interestingly, CBFA2T3 
gene encode for a protein of the same family of ETO and, functionally, these two chimeric 
protein could be considered equal51. Alterations of the CBF are prognostic markers of good 
prognosis, and a specific subtype of AML, known as core-binding factor AML (CBF-AML), has 
been define base on that. Nevertheless, the CBF-AML patients are predicted to have a good 
outcome as long as there are no other negative prognostic markers such as FLT3-ITD or KIT 
mutations48. 
CCAAT/enhancer binding protein α (C/EBPα) loss of function mutations 
Another important transcriptional factor required for the myeloid differentiation is encoded form 
the CCAAT/enhancer binding protein α (C/EBPα) gene, localize on the chromosome 1936. 
Frameshift mutations in the N-Termini portion of the gene, as well as small InDels in the C-
Termini have been reported in approximately 4% - 6% of AML patients and, typically, both 
mutations could co-exist. Interestingly, the presence of C/EBPα loss-of-function lesions is 
typically associated with a better outcome, likewise the previously reported CBF-AML cases.52 
PML/RARα and acute promyelocytic leukemia 
Exclusively associated with the acute promyelocytic leukemia (APL) the extremely recurrent 
chromosomal translocation t(15;17) generates gene fusions involving the retinoic acid receptor α 
(RAR) gene and several different partner genes. The most common fusion is PML/RARα in which 
PML inhibits the function of RARα by a dominant negative effect mediated by the recruiting of 
co-repressor complex, likewise described in the AML1/ETO, CBFB/SMMHC and ETV6/AML1 
fusions53. Remarkably, over the 90% of PML/RARα-positive cases could be successfully treated 
with all-trans retinoic acid (ATRA) that is able to induce the differentiation of this leukemic cells 
into mature granulocytes48. 
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Figure 3. CBF complex genes rearrangements in acute myeloid leukemia (AML). (A) In normal 
cells, heterodimeric AML1-CBFβ transcription-factor complex binds to the DNA sequence TGTGGT in 
the transcriptional regulatory region of AML1-regulated target genes and activates transcription through 
the recruitment of coactivators. (B) In AML cells with the t(8;21) translocation, the N-terminal part of 
AML1 fuses with the C-terminal portion of ETO. The resultant chimeric protein continues to interact with 
CBFβ and to bind to the core enhancer sequence; however, ETO recruits a nuclear corepressor complex 
and results in the dominant repression of AML1-regulated target genes. Similarly, the CBFβ-MYH11 
chimeric protein encoded by the inv(16) mutation continues to interact with AML1; however, instead of 
allowing AML1 to interact with DNA, this chimeric protein recruits AML1 into functionally inactive 
complexes in the cytoplasm. From Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N 
Engl J Med. 1999 Sep 30;341(14):1051-62. 
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Mixed lineage leukemia (MLL) gene alterations 
Localized on chromosome 11q23, the mixed lineage leukemia (MLL) gene, also called ALL-1, 
HTRX or HRX, is one of the most frequently rearranged gene in AML. About 20% of pediatric 
AML patients show alterations of MLL gene, and the incidence rise up to 40% - 65% within the 
FAB subtype M4/M5, in the infant-AML, and in tAML secondary to topoisomerases II inhibitor 
treatment48,54. Encoding for a histone methyltransferase that plays an essential role in early 
development and hematopoiesis, the MLL gene could be involved in chromosomal translocations 
that lead to in-frame fusion with more than 60 different partner genes55 (Figures 4, 5). 
Additionally, partial tandem duplication (PTD) within the MLL gene were also reported (Figure 
5). The predicted effect in both cases is the deregulation of the function of the MLL protein 
complex that results in an aberrant expression of target genes crucial for the correct 
hematopoiesis, such as the HOX genes. Generally, chromosomal abnormalities involving MLL 
gene are indicators of poor prognosis of the disease55.  
 
 
Figure 4. Distribution of major MLL fusion partner genes in de-novo childhood and adult 
leukemias. Mixed lineage leukaemia (MLL) rearrangements are found in approximately 5% of acute 
lymphoblastic leukemias (ALL), approximately 5–10% of acute myeloid leukemias (AML) and virtually 
all cases of mixed lineage (or biphenotypic) leukemias (MLL). Major MLL fusion partner genes are AF4, 
which is predominantly found in ALL; AF9, which is predominantly found in AML; and ENL, which is 
found in both ALL and AML. From : AV Krivtsov AV, Armstrong SA. MLL translocations, histone 
modifications and leukaemia stem-cell development Nature Reviews Cancer. 2007; 7, 823-833. 
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OTT/MAL and acute megakaryoblastic leukemia 
Specifically recurrent in the pediatric FAB M7 AML, the translocation t(1;22) has been overall 
reported in approximately 3% of childhood AML patients. Among them, almost all the patient 
are infant (< 18 months of life). Due to this chromosomal rearrangement, the RNA Binding Motif 
Protein 15 (RBM15, also named OTT) gene is in-frame fused with the Mitogen-Activated Protein 
Kinase Kinase (MLK1, also named MAL) gene. The result is the expression in the leukemic cells 
of a chimeric OTT/MLK1 fusion protein which de-regulates the NOTCH1 signaling leading to 
the arrest of the differentiation56. The presence of this genetic lesions is typically associated with 
a worst outcome48. 
 
Figure 5. Schematic representation of the MLL protein and MLL fusions. (A) The mixed lineage 
leukaemia (MLL) gene is approximately 89 kb long, consists of 37 exons14,and encodes a 3,969 amino 
acid nuclear protein with a complex domain structure (unique domains are highlighted). The mature MLL 
protein consists of two non- covalently associated subunits (MLLN (300 kDa) and MLLC (180 kDa)) 
produced by cleavage of nascent MLL by taspase 1 after amino acid residues 2,666 (cleavage site 1 
(CS1)) and 2,718 (CS2)18. Proteins that bind to specific domains are noted above each domain. The N-
terminus contains three short AT-hook motifs (ATH 1–3), which are thought to mediate binding to the 
minor groove of AT-rich genomic DNA sequences. There are two speckled nuclear localization sites 
(SNL1 and SNL2) immediately C-terminal to the AT-hooks that are followed by a transcriptional 
repression domain (TRD) consisting of two functional subunits, RD1 and RD2. RD1 contains a DNA 
methyltransferase (DMT) homology domain that includes a CxxC zinc-finger motif that may recruit 
proteins such as HPC2 and the transcriptional co-repressor CtBP34. RD2 recruits histone deacetylases 
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HDAC1 and HDAC2 (REF. 34). The plant homology domain (PHD) zinc-finger motifs may mediate 
binding of the cyclophilin, CYP33, and potentially other proteins. The transcriptional activation (TA) 
domain recruits the transcriptional co-activator CBP (CREB-binding protein) and precedes a C-terminal 
SET (Su(var)3-9, enhancer-of-zeste, trithorax) domain that possesses histone H3 lysine 4 (H3K4) 
methyltransferase activity22,28 and is structurally homologous to Drosophila melanogaster trithorax. The 
breakpoint cluster region (BCR) spans exons 8–13. (B) Structure of MLL fusion proteins generated by 
MLL translocations. A typical MLL fusion protein contains the N terminus of MLL encoded by the first 8 
to 13 exons and the C terminus of one of over 50 fusion partner genes (FPGs). (C) A unique MLL 
rearrangement results in MLL–partial tandem duplication (MLL–PTD). MLL–PTD contains a varied 
number of exons 5 to 12 duplicated and inserted before exon 11 or 12.. From : AV Krivtsov AV, 
Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development Nature 
Reviews Cancer. 2007; 7, 823-833. 
 
1.1.5 Prognostic markers and risk stratification 
The heterogeneity in response to therapy and overall outcome of the different type of pediatric 
AML have always pushed for the identification of prognostic markers useful for stratifying the 
patients in the correct risk classes4. Nowadays, due to the novel insight, traditional prognostic 
markers such as age ad diagnosis, weight, white blood count, FAB subtype, have been replaced 
by novel, and more reliable markers based on cytogenetic and molecular features, as well as flow 
cytometric assessment of minimal residual disease (MRD) 4. Table 3 summarizes the most 
recurrent genetic abnormalities identified in pediatric AML that have a prognostic relevance, 
together with those likely to have clinical relevance, and others with unknown (but potential) 
relevance. 
Therapy response and MRD monitoring 
Even if several cytogenetic and genetic prognostic markers are now available, still  a large 
number of children with AML lack clinically informative karyotypes and are not eligible to risk-
based therapy allocation based solely on cytogenetic subgroups.15 Overall, clinically significant 
cytogenetic lesions and somatic mutations account for only about 35% of pediatric AML15. 
Furthermore, the recently discovered recurrent mutations affecting Isocitrate Dehydrogenase 1 
[IDH1], Isocitrate Dehydrogenase 2 [IDH2] and DNA (cytosine-5-)-methyltransferase 3 alpha 
[DNMT3A] genes in adult AML (demonstrated to have a prognostic relevance) are no present in 
the pediatric AML57–59. So far, despite the constant increase in the knowledge of AML 
mutational landscape, the most important prognostic factor in AML is the response to therapy 
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assessed by MRD60. RNA-based polymerase chain reaction (PCR) analysis of leukaemia-specific 
gene fusions, quantitative PCR (qPCR), and flow cytometric detection of aberrant 
immunophenotypes60 are the most reliable methods through with it is possible to monitor the 
response to the treatment and early-reveal the rise of a relapse. Although RT-PCR detection of 
fusion transcripts is sensitive to a level of 0.01–0.001%, it can be used in only about 50% of 
cases. Moreover, persistent expression of some gene fusion (such as AML1/CBFA2T3 and 
CBFβ/MYH11) can be present also in patients who are in long-term remission, indicating the 
possibility to detect false-positive. Conversely, the sensitivity of flow-based MRD assays is only 
0.1–0.01%, but this technique can be applied to more than 90% of cases6. In the ongoing 
Children’s Oncology Group (COG) de-novo AML trial, the combination of diagnostic molecular 
risk factors with the post-induction response assessment by MRD detection has allowed risk 
assessment in all patients with AML, demonstrating the ability to correctly classify even those 
patients with clinically non-informative karyotypes15 (Figure 6) . 
 
Figure 6. Newly devised risk stratification for AML. (A) Overall disease-free survival for all patients is 
presented. (B) Incorporation of known cytogenetic and molecular risk factors creates a 3-tier risk-
stratification schema, allocating 35% of patients to cyto/molecular high risk (10%) or low risk (25%), 
with 65% of patients without informative cyto/molecular markers remaining in the standard-risk group. 
(C) Incorporation of disease assessment by multidimensional flow cytometry after the initial induction 
allows for identification of risk groups within the standard-risk cohort, providing a 2-tier risk stratification 
schema by combining the cyto/molecular and minimal residual disease (MRD) data. From Tarlock K, 
Meshinchi S. Pediatric Acute Myeloid Leukemia: Biology and Therapeutic Implications of Genomic 
Variants. Pediatr Clin North Am. 2015 Feb;62(1):75-93. 
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Table 3. Genetic lesions in pediatric acute myeloid leukemia 
Karyotype Affected genes %δ Clinical significance 
t(8;21)(q22;q22) RUNX1-RUNX1T1 15 Favourable prognosis; Not candidates for HSCT 
inv(16)(p13.1;q22) 
t(16;16)(p13.1;q22) CBFB-MYH11 10 
Favourable prognosis 
Not candidates for HSCT 
−7 Unknown 1 Poor prognosis 
11q23 MLL rearrangements 20  
 MLL-MLLT11  Favourable prognosis t(1;11)(q21;q23) MLL-MLLT3 1 Intermediate prognosis 
t(9;11)(p12;q23) MLL-MLLT4 8 Poor prognosis 
t(6;11)(q27;q23) MLL-MLLT10 1 Poor prognosis 
t(10;11)(p12;q23)  1 Intermediate prognosis Others  9  t(1;22)(p13;q13) RBM15-MKL1 1 Megakaryoblastic leukaemia; Unknown prognosis 
t(6;9)(p23;q34) DEK-NUP214 1 Poor prognosisγ 
t(8;16)(p11;p13) KAT6A-CREBBP 1 Poor prognosisγ 
t(16;21)(q24;q22) RUNX1-CBFA2T3 1 Poor prognosisγ 
Normalε FLT3-ITD 12 Poor prognosis if high ratio of mutant to wild-type allele; May benefit from HSCT or treatment with FLT3 inhibitors 
Normalε NPM1 8 Favourable prognosis except in cases with FLT3-ITD 
Normalε CEBPA 5 Favourable prognosis probably limited to cases with biallelic mutations 
Normalε 
WT1   Mutation 10 Unknown 
SNP rs16754 25 May be associated with favourable outcome 
Normalε 
IDH1 and IDH2   Mutation 4 Unknown 
IDH1 SNP rs11554137 10 Unknown 
Normalε RUNX1 Rare Unknown 
Normalε TET2 Rare Unknown 
Normalε DNMT3A Rare Unknown 
t(15;17)(q22;q12) PML-RARA NA Observed only in APL; Favourable outcome 
HSCT, haematopoietic stem-cell transplantation; ITD, internal tandem duplication; SNP, single 
nucleotide polymorphism; NA, not available; APL acute promyelocytic leukaemia. δ, Percent of non-APL 
cases with each abnormality. Note that some alterations co-exist, such as NPM1 mutation and FLT3-ITD. 
γ, The poor prognosis of these rare translocations has been firmly established only in adult AML. ε, These 
mutations often occur in cases with normal karyotypes, but are also seen in cases with other 
abnormalities. From Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br J Haematol. 2012 
Nov;159(3):259-76. 
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1.2 Mutational landscape of cytogenetically normal acute 
myeloid leukemia (CN-AML) as drawn by next-generation 
sequencing, state of art 
The first insights into AML molecular pathogenesis originated from cloning the breakpoints of 
recurrent chromosomal translocations detected by conventional cytogenetics61. The identification 
of recurrent chromosomal rearrangements and the association of those with clinical data have 
been crucial for risk stratification of patients and development of risk-adapted therapies62. 
However, approximately 20% of pediatric and 43% of adult AML patients do not show any 
known chromosomal aberrations and, so far, these are generically define as cytogenetically 
normal AML (CN-AML) 6 (Figure 7). Historically belonging to the intermediate-risk class, the 
CN-AML patients have always showed a great variability in therapy response and overall 
outcome, underlining the presence of other genetic changes not detectable by conventional 
cytogenetic analysis but relevant for pathogenesis, dynamics, and outcome of AML61. With the 
aim of investigating the mutational landscape of CN-AML, lately, several studies have taken 
advantage of the novel next-generation sequencing (NGS) technologies, and novel important 
insights in the molecular pathogenesis of CN-AML have been achieved, especially in adults57,63–
65. 
 
Figure 7. Karyotypic alterations in both pediatric and adult AML. Approximately 20% of pediatric 
and 43% of adult AML patients do not show any known chromosomal aberrations and, so far, these are 
generically define as cytogenetically normal AML (CN-AML). From Tarlock K, Meshinchi S. Pediatric 
Acute Myeloid Leukemia: Biology and Therapeutic Implications of Genomic Variants. Pediatr Clin North 
Am. 2015 Feb;62(1):75-93. 
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1.2.1 The modern genomic era and AML gene discovery61 
In 2008, only 8 years later the conclusion of the Human Genome Project, the first human cancer 
genome was sequenced. The DNA from leukemic blasts of an adult patient with CN-AML (FAB 
M1) was analyzed by whole-genome sequencing in two years63. Subsequently, a second AML 
M1 genome64 (in 2009) and an APL M3 genome66 (in 2011) were analyzed within the following 
three years (2009-2011), in no more than six weeks in the latter case. 
1.2.1.1  Re-definying the molecular profile of adult AML 
Beyond the single somatic mutations identified by the above mentioned studies, two important 
aspects need to be here considered. First, these studies described for the first time that in adult 
AML, somatic mutations are frequent in genes encoding for epigenetic modifiers  (eg. TET2, 
DNMT3A, Additional Sex Combs Like 1[ASXL1]), revealing a novel class of genes commonly 
altered in AML (Class III) other than pro-survival and impairing myeloid differentiation as 
described in the “two-hit” model of leukemogenesis61 (Figure 8) . Additionally, these studies 
represented a technical paradigm of how the next-generation sequencing could be successfully 
used for mutations discovery studies67. Indeed, starting from here, in the last years we were 
witness of a constantly increase of studies in which next-generation sequencing has been used for 
mutation discovery in leukemia as well as in other cancers. The decrease in time and costs will 
soon allow a broadly use of this technology for routinely diagnostic and in clinics, paving the 
way to a complete personalized therapy in cancer treatment. So far, the bigger effort to 
investigate the mutational landscape of adult CN-AML has been coordinated by The AML 
Cancer Genome Atlas project (TCGA) study in which the most modern sequencing and 
genotyping techniques have been used to investigate the somatic genome of 50 patients with de-
novo AML and the somatic exome of additional 150 cases68. Briefly, this study discovered that 
adult AML genomes have far fewer mutations compared to other types of adult cancers, with an 
average of 13 mutations per individual. A total of 23 genes were reported as being substantially 
altered (NPM1, FLT3, DNMT3A, IDH1 or IDH2, NRAS or KRAS, AML1, TET2, TP53, C/EBPα, 
WT1, and KIT) 68 (Figure 9) . Additionally, the study confirmed the recurrence of previously 
reported chromosomal alterations, such as t(15;17), t(8;21), inv(16), abn11q23, monosomy 5, 
and monosomy 7. Remarkably, the study was also able to identified novel translocations below 
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the detection level of conventional cytogenetics, underlining the important role of fusion genes in 
the development of AML61 (Figure 10) .  
Figure 8. Complementation groups of genetic changes in AML. From Meyer SC, Levine RL. 
Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014 
Aug;15(9):e382-94. 
Based on the overall finding from the TCGA study, several interesting comments can be made: i) 
the traditional concept of Class I and Class II mutations for leukemogenesis has been radically 
modified (Figure 8), considering that just 59% of AML cases analyzed showed mutations in 
oncogenic signaling components (which were previously believed to be essential for leukaemic 
transformation) 61. ii) This study, as well as the previous NGS studies on adult AML, strongly 
demonstrate the recurrence of mutations in epigenetic factor genes such as TET2 and DNMT3A, 
defying a novel class of genes that could be mutated in adult AML with possible implications in 
prognostic and/or therapeutic. iii) Rare but not-random mutations in cohesion genes and genes 
encoding for component of the spliceosome-complex (so far not associated with this pathological 
setting) has been described, paving the way to the definition of additional mutations class in 
adult AML. 
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Figure 9. Characterization of mutations in adul AML. Significantly mutated genes found by TCGA 
study in adult AML. From Cancer Genome Atlas Research Network. Genomic and epigenomic 
landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013 May 30;368(22):2059-74. 
 
1.2.1.1  The landscape of genetic alterations in childhood AML 
Despite the insights recently achieved by the TCGA study on the mutational profile of adult 
AML, and the confirmation of the recurrence and clinical utility of several somatic mutations in 
adult AML (such as DNMT3A and IHD1), these mutations appear to be rare or absent in 
childhood AML,58,59,69 underlying once again the significant differences between AML in elderly 
and young patients15 (Figure 11 and Figure 12). Based on that evidence, two different 
cooperative studies are ongoing with the overall aim to investigate the genomic and epigenomic 
profiles for the spectrum of childhood AML:1,70 the St. Jude/Washington University Pediatric 
Cancer Genome Project (PCGP) (http://www.pediatriccancergenomeproject.org/site/), and the 
COG/National Cancer Institute (NCI) Therapeutically Applicable Research to Generate Effective 
Treatments (TARGET) AML initiative (https://ocg.cancer.gov/programs/target). Early data from 
these two studies have already provided new biological insights in pediatric AML. Among them, 
analyzing by RNA-seq the whole-transcriptome from leukemic cells of a cohort of pediatric 
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patients with acute megakaryoblastic leukemia (AML FAB M7), recently, the PCGP discovered 
a novel  
 
Figure 10. AML gene fusions. (A) is a plot created with the use of Circos software29 showing in-frame 
(green) and out-of-frame (orange) gene fusions detected in the AML cohort in the Cancer Genome Atlas 
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(TCGA) with the use of Trans-ABySS software. Ribbon widths are proportional to the frequency of a 
fusion event. Chromosomes are individually colored and are arranged clockwise from chromosome 1 to 
X, starting with chromosome 1 at 12 o’clock. No rearrangements involved the Y chromosome. The 
frequencies of in-frame and out-of-frame gene fusions are shown in (B) and (C), respectively. For gene 
names shown in red, one of the partner genes in that fusion was found to be mutated in at least one other 
AML sample from this data set. On the basis of chromosomal aberrations and genomic variants annotated 
in the Mitelman database from the Cancer Genome Anatomy Project (CGAP) 
(http://cgap.nci.nih.gov/Chromosomes/Mitelman), all previously identified gene fusions are shown in 
blue, a single known polymorphic fusion is shown in green, and all novel events are shown in red. From 
Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute 
myeloid leukemia. N Engl J Med. 2013 May 30;368(22):2059-74. 
cryptic inversion of the chromosome 16 leading to the in-frame fusion of the CBFA2T3 and 
GLIS2 genes. Remarkably, within the M7 subtype, this alterations seems to be extremely 
recurrence (about 30% of children with FAB M7 AML, not associate with Down syndrome) and 
predicts for a poorer outcome71. On the other side, the TARGT AML initiative, by the means of 
whole-genome sequencing and RNA-seq, analyzed an initial cohort of more than 200 children 
with AML (diagnosis, remission and relapse matched analysis), discovering an high frequency of 
ETV6 mutations in childhood CN-AML (up to 6% of cases) which are significantly associated 
with a worst outcome. Moreover, this study also revealed a significant clonal evolution of the 
diagnostic predominant leukemic clone between diagnosis and relapse, with approximately a 
third of total mutations identified at diagnosis that persisted at relapse together with the 
acquisition of a lot of novel mutations1. Nevertheless, so far, the mutational landscape of 
pediatric CN-AML remains hazy, and additional coordinated efforts need to be made in order to 
fully characterize the molecular heterogeneity of this particular subtype of childhood leukemia. 
The rise of NGS has provided the tools for comprehensive interrogation of the cancer genome 
and the emerging data will be crucial to define new biomarkers and drug-targeted mutations, 
leading, ultimately, to make personalized medicine a reality in the near future1,15. 
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Figure 11. Somatic mutations in adults and childhood AML. (A) Prevalence of AML-associated 
mutations in pediatric versus adult AML, demonstrating lower incidence of mutations in pediatric AML. 
Bordered panel shows 2 newly discovered mutations in adults that are absent in pediatric AML. 
 
Figure 12. Age-based somatic mutations groups in adults and childhood AML. (B) Age-based 
prevalence of common AML-associated mutations. 
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AIMS 
  
 
The overall aim of this research project was to investigate through RNA-seq the mutational 
landscape of pediatric cytogenetically normal AML patients negative for all the currently known 
somatic mutations reported in CN-AML. 
The rationale to analyze this specific subtype of pediatric acute myeloid leukemia was driven by 
the fact that these patients do not show any cytogenetic or molecular aberrations so far known in 
AML, representing the “all-neg” AML subgroup. 
Due to the lacking of any prognostic marker, “all-neg” AML patients were historically classified 
in the intermediate-risk class. However, these patients had always showed a great variability in 
response to therapy and overall outcome, underlining the presence of unknown genetic changes, 
not detectable by conventional analyses, but relevant for pathogenesis, dynamics, and outcome 
of AML. 
The results obtained from this study are expected to reveal novel biological insights into the rise 
of pediatric AML, to define novel prognostic markers and putative therapeutic targets, and to 
prospectively ensure, a correct risk stratification and risk-adapted therapy also for the “all-neg” 
AML subgroup. 
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CHAPTER II – Study design and 
Methods 
2.1 Patients 
Patients analyzed either in the massively parallel sequencing screening or in the validation cohort 
are children with newly diagnosed de novo AML other than acute promyelocytic leukemia 
enrolled in the AIEOP AML 2002/01 Protocol 72. The initial diagnosis of AML was centrally 
established according to morphology-FAB classification and immunophenotypic analysis at the 
laboratory of Pediatric Hematology of the University-Hospital in Padova. Chromosome analysis 
was performed on BM using standard laboratory procedures. The karyotypes were reported 
according to the International System for Human Cytogenetic Nomenclature (ISCN 2005). For 
fluorescence in situ hybridization (FISH) an MLL locus specific (LSI) dual color probe for 
11q23 (Abbot-Vysis, Downess Grove, IL) was employed. This analysis was performed on 
metaphases and/or nuclei, when necessary, according to the manufacturer’s instructions. Patients 
were all negative for any known cytogenetic aberrancy and recurrent genetic abnormalities 
involving MLL, CBFB, and FLT3 genes. Main clinical characteristics of the 19 AML patients 
analyzed by RNA-seq are reported in Table 4. 
2.2 Whole-transcriptome sequencing 
2.2.1 RNA-seq libraries preparation 
Total RNA was extracted from BM leukemia cells of CN-AML patients by TRIzol, following 
the manufacturer’s protocol (Invitrogen, Karlsruhe, Germany); 250 to 1000 ng of total RNA was 
used for the synthesis of cDNA libraries with TruSeq RNA Sample Prep Kit v2 (Illumina, San 
Diego, CA) according to the manufacturer’s recommendations. Briefly, by the use of magnetic 
beads, PoliA+ RNA have been selected and purified from total RNA. Then, through incubation 
for 4 minutes at 94°C, the purified PoliA+ RNA have been fragmented (average length of 160bp) 
and sequentially retro-transcribed to cDNA by SuperScript II Reverse Transcriptase (Invitrogen) 
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and Random Examers Primers (Illumina), according to Illumina’s libraries preparation protocol. 
cDNA were then purified by Agencourt AMPure XP (Beckman Coulter) magnetic beads 
purification system, and directed through the ends-adenilation step.  
Table 4. Table 4. Clinical characteristics of the 19 AML patients analyzed by RNA-seq 
# ID Age (y) Gender FAB 
WBC, 
x 
109/mL 
BM 
blast, % 
at 
diagnosis 
HSCT 
(type) 
Relapse 
(site) Status 
1 CN-AML#1 0.3 F M5A 18000 88 AUTO - Vivo 
2 CN-AML#2 0.3 M M4 82190 60  MFD - Vivo 
3 CN-AML#3 0.5 F M7 22800 40 - - Morto 
4 CN-AML#4 0.8 M M2 22400 52 MUD - Vivo 
5 CN-AML#5 1.4 M M7 22400 60 MUD - Vivo 
6 CN-AML#6 1.4 M M0 35000 86 MUD - Vivo 
7 CN-AML#7 1.5 F M7 13370 90 MMUD - Vivo 
8 CN-AML#8 0.8 M M7 188000 28 MFD Yes Morto 
9 CN-AML#9 15.5 M M5A 99420 90 AUTO - Vivo 
10 CN-AML#10 6.5 F M1 7870 70 AUTO Yes Vivo 
11 CN-AML#11 8.1 M M1 3500 70 AUTO Yes Vivo 
12 CN-AML#12 4.6 F M1 9980 90 MMFD - Vivo 
13 CN-AML#13 9 M M0 1220 70 MUD - Vivo 
14 CN-AML#14 8.9 M M5 96180 60 MUD - Vivo 
15 CN-AML#15 3.4 M M2 12010 70 AUTO Yes Vivo 
16 CN-AML#16 0.1 F M2 16000 41 MUD - Vivo 
17 CN-AML#17 1.4 M M0 8470 70 AUTO - Vivo 
18 CN-AML#18 2.9 M M1 187900 90 AUTO Yes Morto 
19 CN-AML#19 0.5 M M0 34770 21 - - Vivo 
BM, bone marrow; HSCT, hematopoietic stem cell transplant; AUTO, autologous; MUD, matched 
unrelated donor; MMUD, mismatched unrelated donor; MFD, matched family donor; MMFD, 
mismatched family donor. 
 
After a second purification, DNA ligase I was used to link the Illumina adapters at the ends of 
each cDNA fragment by incubation of 1 hour at 16°C. The ligation products were then submitted 
for a PCR amplification step with primers that map on the adapters (Illumina) which ensure the 
enrichment of the only cDNA fragments that have been correctly linked to the adapters. Finally, 
one last purification step through Agencourt AMPure XP (Beckman Coulter) magnetic beads is 
perform to obtain the final libraries ready to be validated, quantified and then loaded for the 
clonal amplification and sequencing. 
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2.2.2 RNA-seq libraries validation and quantification 
All the libraries have been validated and quantified accordingly to Illumina’s protocol. The 
average length distribution of the cDNA fragments of a library has been evaluated through 
analysis by Chip DNA 1000 on Bioanalyzer 2100 (Agilent Technologies). The concentration of 
each library has been evaluated through two different methods: i) quantitative-PCR (qPCR) 
using primer mapping on the Illumina adapters linked at the end of each cDNA fragments with 
KAPA SYBR® FAST qPCR Kits (KAPA Biosystems); ii) fluorimetric analysis by Quant-iT™ 
PicoGreen® dsDNA Assay Kit (Invitrogen). An average of the concentration obtained by these 
two assays were taken as library final concentration and used to dilute the each library to 10 
ng/μl as indicated in Illumina protocol. 
2.2.3 Bridge-Amplification and sequencing on HiScanSQ (Illumina) 
After the quantification, 100ng total of each library was pooled with the other libraries according 
to the pooling strategy and the adaptors used in the library preparation step. Then, through the 
cBot cluster amplification system / TruSeq PE Cluster Kit v3-cBot-HS (Illumina) the libraries 
were load into 8 lane of glass slide (flow-cell). By complementary oligo-adapters linked on the 
flow-cell, each fragment of the cDNA library was anchored and, through a “bridge” solid-phase 
amplification, clonally amplified to generate a cluster of cDNA all derived from the same 
starting fragment of the library. Sequencing by synthesis was performed on HiScanSQ sequencer 
(Illumina) at 75bp in paired-end mode. An average of 6.6 Giga Base (GB) and 87.6 million of 
reads has been generated for each patient. The average coverage obtained was 34X. 
2.3 Bioinformatic analysis 
75x2 paired-end reads obtained by RNA-seq were trimmed at 74 nucleotides after checking the 
average of the base quality at each position. The reads were aligned to the reference human 
genome HG19/GRCh37 with TopHat2/BowTie273 with a percentage of mapping reads ranging 
from 50% to 84% and a mean depth of 35x. For each sample the mean depth was computed 
considering the observed portion of reference genome covered instead of the whole human 
transcriptome: 
28 
 
𝑀𝑒𝑎𝑛 𝐷𝑒𝑝𝑡ℎ =  
𝑁 ∗ 74
𝐿  
where N is the number of mapped reads and L is the total size of the regions covered by at least 
one read. By this we purpose to estimate a different transcriptome size for each sample keeping 
out the regions not expressed and including the putative unknown transcript. The presence of 
gene fusions in the samples was investigated with three different bioinformatic software 
packages suited to detect chimeric transcripts from RNA-seq data: Defuse,74 ChimeraScan,75 and 
FusionMap.76 Only the putative chimeric transcripts detected from all the alghotihms were 
selected for further validations. 
2.4 RNA isolation, RT-PCR and Sanger sequencing 
Total RNA was extracted using Qiagen RNeasy mini kit (Qiagen) as per manifacturer’s 
instructions. Then quantity and quality of the isolated RNA was assessed using the Nanodrop 
(Thermo Scientific). 
Table 5. List of the primers used for RT-PCR and Sanger sequencing 
Amplicon target Primer Fw Tm %GC Primer Rev Tm %GC Amplicon lentgh (bp) 
CBFA2T3-GLIS2 CATGTCGGAGCTGCAGAAAG 58 55 
CAAAGAGCTGGT
TACACTTGGCC 61 52 353 
NUP98-PHF23 GGCCCCAGTAGCTTTGACAGAT 60 55 
GCAGACGAGAGA
AAGTGGACCT 61 57 216 
NUP98-KDM5A CCAGCAGCACATCAATAGTCTAACA 59 44 
GCTCCTTTGATTT
GTCTGCACC 60 50 278 
PRDM16-SKI GCTGCTTCTGGACTCAAGGAGG 61 59 
TATTGGAAGAGC
CGGCCAAG 61 55 210 
MYB-GATA1 AGCACAAAATGTCTCCAGTCATGTT 60 40 
TCCTTCCGCATGG
TCAGTG 59 58 351 
MAML1-
SQSTM1 
CAGTACCAAGACC
CGACACAAG 58 55 
ACACAAGTCGTA
GTCTGGGCAG 58 55 303 
RUNX1-USP42 GGAGCTTGTCCTTTTCCGAGC 61 57 
GCATGACATGTTT
TGGAGTGTTC 58 43 364 
DHH-RHEBL1 TCCACTACGAAGGCCGTGC 61 63 
GGATCGTAGCCTT
CCGAGAAC 59 57 205 
TNIP1-PDGFRB CCGGAATACACCTGGCGTCTAC 62 59 
CCATCGGATCTCG
TAACGTGG 61 57 216 
 
Typically, 500-1000 ng of total RNA was retrotrascribed to cDNA using oligo-dT and random 
hexamers by Transcriptor First Strand cDNA Synthesis kit (Roche Diagnostics). RT-PCR 
reaction was performed according through the AmpliTaq GOLD kit (Applied Biosystems). PCR 
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amplicons were purified using a Microcon centrifugal filter (Millipore Corporation) and 
sequenced according to the BigDye terminator v 3.1 Cycle Sequencing kit (PE Applied 
Biosystems) on an Applied Biosystems 310 analyzer. BLAST 
(http://www.ncbi.nlm.nih.gov/BLAST)  and CLC (CLC Bio - Quiagen) software were used for 
the analysis of sequence. A list of the primers used for RT-PCR and Sanger sequencing is 
reported in Table 5. 
2.5 Gene expression analysis from RNA-seq data 
The mapped reads obtained with TopHat2/BowTie2 pipeline were processed with SAMtools77 in 
order to remove the potential optical or PCR duplicate (function “rmdup”) and then the count of 
the mapped reads for each hg19 gene was performed by applying the Python package “htseq-
count” (http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html). Gene annotations 
were derived from Ensembl Release 70 (January 2013). The differentially expressed genes were 
determined with edgeR, a R-bioconductor package suitable for analyzing RNA-seq data.78 Three 
different comparisons were performed, corresponding to all the possible couples among the three 
groups of patients: 1) DHH-RHEBL1- positive and CBFA2T3-GLIS2-positive (N=2); 2) DHH- 
RHEBL1-negative and CBFA2T3-GLIS2-positive (N=2); 3) CN-AML (N=4). For each 
comparison, the complete set of genes, with the corresponding mapped reads count, was firstly 
reduced in order to consider in our analysis only the genes with count-per-million (CPM) > 3 in 
more than 2 samples. Then, adopting a statistical method based on the negative binomial 
distribution, the significance of the differences between the normalized reads count was 
determined for each gene. Differences with P<0.05 were considered to be statistically significant. 
The Multi Experiment Viewer (MeV) tool (http://www.tm4.org/mev.html) was used to visualize 
the expression data. Expression levels of PRDM16 and USP42 genes were obtained from the 
RNA-seq data according the same bioinformatics analysis described above. Graphpad Prims 
(GraphPad Software) was used to visualize the expression data. 
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2.7 Quantitative (q) PCR for USP42 and PRDM16 genes 
Expression levels of USP42 were measured by qPCR. Total RNA was obtained from BM blasts, 
and CD34+ haematopoietic cells; 500ng total RNA was reverse-transcribed to single-stranded 
cDNA using the Transcriptor first strand cDNA synthesis kit (Roche Diagnostics) with oligo-dT 
primers (2.5 μM). Gene-specific primers amplifying USP42 wild-type (wt) allele, and USP42 wt 
plus fused variant (wt+fus) were designed with Primer Express 3.0 Software (Applied 
Biosystems) and qRT-PCR was performed using FastStart Sybr Green (Roche Diagnostics) on 
the LightCycler 480 apparatus (Roche Diagnostics). DDCt method was used to quantify gene 
product levels relative to two housekeeping genes, GAPDH, and ATPS. qPCR primer sequences 
were as follows: USP42-wt_Fw,5’-CTGGGGTGCTGTGTCTTCAT-3’;USP42-wt_Rev,5’- 
GCTGCATTGGCAAAACAGGT-3’;USP42-wt+fus_Fw,5’-TGCAAGGGCGTTTCAGATACT-
3’; USP42-wt+fus_Rev,5’-GTTCCGGCTTCACAAACTGC-3’. All qPCR primer pairs spanned 
intron/exon boundaries. USP42 alleles (wt and wt+fus) expression levels were analyzed in the 
t(7;21)-positive sample, in CN-AML cases (N=4), and in CD34+ haematopoietic cells (N=1). q-
PCR analysis was also performed in order to detect differential expression of the PRDM16 gene 
in the t(7;21)(p22;q22) positive case (AML74), and in five paediatric CN-AML samples (CN21, 
CN23, CN25, CN65, CN68). 
2.8 Fluorescence in situ hybridization (FISH) analysis for 
NUP98-PHF23 fusion 
Fluorescence in situ hybridization (FISH) analysis was performed on metaphase e interphase 
cells using two BlueFISH probes (BlueGnome Ltd., Cambridge) for chromosome 11 and  17 
according to manufacturer’s instructions. Specifically, BAC clones RP11-120E20 and RP11-
348A20 (red) were used to probe the NUP98 gene on chromosomes 11, while the BAC clone 
RP11-542C16 (green) was used to target the PHF23 gene on chromosome 17. 
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2.9 Cloning and retroviral transduction of TNIP1-PDGFRB 
fusion 
Full length TNIP1-PDGFRB chimeric transcript was amplified by PCR (Phusion® High-Fidelity 
DNA Polymerase, New England Bio Labs Inc.), cloned into pCR2.1®-TOPO® TA vector (Life 
Technologies) and then sub-cloned in murine stem cell virus (MSCV)-internal ribosome entry site 
(IRES)-green fluorescence protein (GFP) vector (MSCV-IRES-GFP retroviral vector). Retroviral 
supernatants containing MSCV-TNIP1-PDGFRB-IRES-GFP, as well as MSCV-IRES-GFP 
(empty vector control) were produced in 293T packaging cell line and used to infect interleukin 
(IL)-3-dependent hematopoietic murine cells (Ba/F3). After 3 days in culture, cells were 
harvested and sorted by flow-cytometry for GPF expression. The expression of the fusion gene 
was confirmed at mRNA and protein level by RT-PCR/Sanger sequencing and western blot, 
respectively. 
2.10 In-vitro functional analyses for TNIP1-PDGFRB fusion 
2.10.1 Cytokine-independent assay 
To evaluate factor-independent growth, Ba/F3 cells were washed three times with PBS 1X, and 
then seeded in triplicate at the concentration of 0.2M cells/well in 24-wells plate with or without 
IL-3. Cell proliferation and viability were assessed every two days for a total of 14 days by 
trypan blue count using TC20™ Automated Cell Counter (Biorad). 
2.10.2 TKIs treatment sensitivity assay 
The potential effect of several TKIs was assessed on both mouse hematopoietic Ba/F3 cells 
expressing TNIP1-PDGFRB-fusion using CellTiter-Blue® Cell Viability Assay (Promega) 
accordingly the manufacturer’s guidelines. A range of drug concentration was used (0.0025μM -
10μM) and the cell viability was assessed 72 hours (hrs) of treatment. IC50 for each TKI used 
was calculated using Graphpad Prims (GraphPad Software). 
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CHAPTER III – Results and 
Discussion 
3.1 Gene fusions are a hallmark of pediatric CN-AML 
Fusion genes are frequently detected in acute myeloid leukaemia as well as other haematopoietic 
cancers. In the present study, RNA-seq performed on diagnostic leukemic blasts of 19 pediatric 
CN-AML cases confirmed the considerable incidence of this type of genetic alteration in 
childhood CN-AML. The presence of gene fusions was investigated with three different 
bioinformatic software packages suited to detect chimeric transcripts from RNA-seq data 
(Defuse,74 ChimeraScan,75 and FusionMap,76) and only the putative chimeric transcripts detected 
from all the alghotihms were selected for further validations. Acconding to this quality selection 
cut-off, a total of 21 putative fusion genes have been identified (Table 6). Based on the incidence 
of the chimeric mRNA in analyzed cases, and the available information on partners genes 
involved in the fusion, the most relevant chimeric transcripts have been selected for further 
analysis as described in the following paragraphs (Figure 13). 
3.2 Identification of CBFA2T3-GLIS2 fusion transcript in 
children with CN-AML 
The most recurrent (3 out of 19 cases, 16%) putative gene fusion revealed by RNA-seq was a 
chimeric transcript involving CBFA2T3 and GLIS2 genes. Resulting from a cryptic inversion of 
the telomeric region of chromosome 16, CBFA2T3-GLIS2 fusion mRNA consists in the 5’ 
portion of CBFA2T3 gene fused in-frame to the 3’ region of GLIS2 gene. CBFA2T3, also known 
as MTG16 or ETO2, is a member of the myeloid translocation gene family that is fused to AML1 
in the t(16;21)(q24;q22) translocation that is identified in therapy-relatedAML.79,80 GLIS2 is a 
transcription factor of the GLI-similar Kruppel-like zinc finger protein family that acts as an 
inhibitor of the hedgehog signaling pathway81. Two patients showed the fusion between exon 11 
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of CBFA2T3 and exon 3 of GLIS2, while the third showed CBFA2T3 exon 10 fused to exon 2 of 
GLIS2 (Figure 14A). 
Table 6. Gene fusion identified by RNA-seq in pediatric CN-AML 
Patient Chromosome 5' gene 3' gene Type Frame Function/Process 
 5' gene 3' gene      CN-AML#1 16 16 CBFA2T3 GLIS2 IC orf 
Trascriptional 
regulation 
CN-AML#2 6 X MYB GATA1 Inter orf 
CN-AML#3 16 16 CBFA2T3 GLIS2 IC orf 
CN-AML#4 16 16 CBFA2T3 GLIS2 IC orf 
CN-AML#4 5 5 MAML1 SQSTM1 Intra orf 
CN-AML#19 6 X MYB GATA1 Inter orf 
CN-AML#8 1 1 PRDM16 SKI Intra oof 
CN-AML#14 1 1 PRDM16 SKI Intra oof 
CN-AML#8 11 12 NUP98 KDM5A Inter orf Chromatin-
modification CN-AML#13 11 17 NUP98 PHF23 Inter orf CN-AML#18 11 17 NUP98 PHF23 Inter orf 
CN-AML#11 5 5 TNIP1 PDGFRB Intra orf Tyrosine-kinase 
CN-AML#14 21 7 RUNX1 USP42 Inter orf 
Signaling CN-AML#3 12 12 DHH RHEBL1 RT orf 
CN-AML#3 12 12 DHH RHEBL1 RT orf 
CN-AML#3 17 17 METRNL SLC16A3 Intra oof 
Other 
CN-AML#7 17 17 METRNL SLC16A3 Intra oof 
CN-AML#4 11 11 LSP1 TNNT3 RT oof 
CN-AML#6 16 16 GSE1 ATP6V0D1 IC orf 
CN-AML#7 2 2 PTMA CXCR4 IC orf 
CN-AML#17 13 13 EPSTI1 ENOX1 RT oof 
IC, intrachromosomal complex; Inter, interchromosomal; RT, read through; Intra, intrachromosomal; orf, 
open-reading-frame; oof, out-of-frame. 
 
These data were also confirmed by RT-PCR analysis and Sanger sequencing (Figure 14B). 
Interestingly, we identified 1 novel breakpoint for the CBFA2T3-GLIS2 fusion transcript 
(CBFA2T3-ex10/ex2-GLIS2), which is different from breakpoints already described in the 2 
recent reports on non-DS AMKL,71,82 demonstrating that the cryptic inv(16) generates a 
CBFA2T3-GLIS2 fusion gene that can be truncated at different positions. 
3.2.1 CBFA2T3-GLIS2 is recurrent in pediatric CN-AML 
To assess the prevalence of CBFA2T3-GLIS2 fusion, we then examined a validation cohort of 
230 children with newly diagnosed de novo CN-AML, also negative for known recurrent genetic 
abnormalities involving MLL, CBFB, NPM1, and FLT3 genes. Globally, the CBFA2T3-GLIS2 
rearrangement was detected in 20 of 237 cases (8.4%) with CN-AML. In the validation cohort 
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RT-PCR analysis and Sanger sequencing confirmed that all positive cases carried the CBFA2T3 
exon 11-GLIS2 exon3 fusion. Fifty percent (N = 10, 50%) of positive patients belonged to the 
M7 FAB subgroup, while the remaining patients (N = 10, 50%) were distributed among the other 
FAB classes (Table 7). These results indicate that the CBFA2T3-GLIS2 fusion transcript, 
recently described as a distinctive feature of pediatric non-DS AMKL,71,82 should be more 
broadly considered as a genetic abnormality that is shared with other FAB subgroups of pediatric 
CN-AML. 
 
Figure 13. Most relevant fusion genes identified by RNA-seq in a pediatric cohort of 19 CN-AML 
patients. Circos representation (http://circos.ca/) reporting only the human chromosome found to be 
involved in rearrangements in the analyzed cases.  
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Figure 14. CBFA2T3-GLIS2 fusion 
transcript is a novel common feature of 
pediatric CN-AML, predicting poorer 
outcome. (A) Schematic representation of the 
fusion between CBFA2T3 and GLIS2 and 
predicted sequence of the fusion proteins 
found in CN-AML. The exon-intron gene 
structures are indicated. The purple blocks 
represent untranslated exons. Black arrows 
indicate the fusion breakpoint. (B) RT-PCR 
analysis and Sanger sequencing performed in 
order to validate the detection of the 
CBFA2T3-GLIS2 fusion. Detection of the 
GAPDH transcript was used as an RNA 
quality control. A library negative for the 
CBFA2T3-GLIS2 fusion transcript was used as 
negative control (Neg). Black arrows indicate 
the fusion breakpoint. (C) Probability of 5-
year EFS in children with CBFA2T3-GLIS2 
fusion transcript in CN-AML. EFS of 
CBFA2T3-GLIS2–positive patients (27.4%, 
SE 10.5) vs CBFA2T3-GLIS2–negative 
patients (59.6%, SE 3.6; P 5 .01). (D) 
Probability of 5-year EFS in pediatric CN-
AML with or without CBFA2T3-GLIS2 fusion 
transcript stratified according to FAB 
subgroups (M7 vs non-M7): EFS of non-M7 
CN-AML without CBFA2T3-GLIS2 (59.4%, 
SE 3.5 vs EFS of non-M7 CN-AML with 
CBFA2T3-GLIS2 (30.0%, SE 14.4 (P5.04). 
EFS of FAB-M7CN-AMLwithout CBFA2T3-
GLIS2 (60.7%, SE 8.3 vs EFS of FAB-M7 
CN-AML with CBFA2T3-GLIS2 (26.6%, SE 
15.0 (P5.04). #1 is in this study CN-AML#1, 
#2 is in this study CN-AML#3, #17 is in this 
study CN-AML#4. From Masetti R, Pigazzi 
M, Togni M Astolfi A, Indio V, Manara E, 
Casadio R, Pession A, Basso G and Locatelli 
F. Blood 2013 121 (17): 3469-3473. 
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Table 7. Clinical features of the CN-AML patients harboring the CBFA2T3-GLIS2 fusion gene 
ID Age, y Gender 
WBC x 
109/L FAB 
Bone marrow 
blast 
percentage at 
diagnosis 
Extra-
medullary 
involvement 
HSCT 
(Type) 
CR 
after 
inductio
n 
therapy 
Relapse 
(site) 
Disease 
free 
duratio
n 
(months
) 
Survival 
duration 
(months) 
#1* 0.8 M 13.63 M2 52 - Yes (MFD) Yes  46.7 +48.0 
#2* 0.3 F 7.52 M5A 88 - Yes (AUTO) Yes 
 90.6 +91.4 
#3 1.4 F 65.08 M0 98 - Yes (AUTO) Yes Yes (BM) 9.3 13.0 
#4 12.7 F 22.8 M1 61 - Yes (AUTO) Yes  70.1 +74.5 
#5 17.0 F 0.91 M1 98 - Yes (AUTO) Yes Yes (BM+skin) 38.7 50.4 
#6 13.3 M 7.52 M5 90 - No No  - 2.6 
#7 0.9 M 7.53 M5 60 - Yes (MUD) Yes Yes (BM) 15.1 19.3 
#8 12.1 M 20.82 M0 70 - Yes (AUTO) Yes Yes (BM) 22.7 24 
#9 17.2 M 35.7 M0 85 - No No  - 3.2 
#10 16.4 F 26.4 M4 70 - Yes (AUTO) Yes Yes (BM) 8.2 12.1 
#11 3.2 F 24.2 M7 70 - Yes (MUD) Yes Yes (BM) 12.2 24.7 
#12 4.0 M 12.79 M7 74 - Yes (MUD) Yes Yes (BM) 8.6 10.7 
#13 0.7 M 13.6 M7 95 Yes (CNS) Yes (MUD) No  - 9.4 
#14 0.7 F 9.6 M7 90 - Yes (MUD) No Yes (BM) - 21.1 
#15 2.0 F 7.4 M7 95 - Yes (MFD) Yes  109.2 +111.8 
#16 1.4 F 128.6 M7 50 - No No  - 2.1 
#17* 0.5 F 13.25 M7 90 - No Yes Yes (BM+CNS) 3.2 5.7 
#18 3.0 F 13.63 M7 40 - Yes (MUD) Yes  37.2 +45.2 
#19 1.6 F 115 M7 90 - Yes (MFD) Yes Yes (BM) 17.7 24.7 
#20 1.9 F 56.5 M7 30 - Yes (MFD) Yes  13.5 +15.6 
*Indicates patients identified in the RNA-seq screening. MUD=Matched Unrelated Donor, MFD=matched family 
donor, AUTO=autologous. BM=Bone Marrow. CNS=Central Nervous System; +=patients alive and in CR. #1 is 
in this study CN-AML#1, #2 is in this study CN-AML#3, #17 is in this study CN-AML#4. From Masetti R, 
Pigazzi M, Togni M Astolfi A, Indio V, Manara E, Casadio R, Pession A, Basso G and Locatelli F. Blood 2013 
121 (17): 3469-3473. 
 
 
3.2.2 CBFA2T3-GLIS2 identifies a subset of childhood CN-AML 
with poor outcome 
We evaluated whether the presence of CBFA2T3-GLIS2 fusion product influences patients 
outcome. The 5-year event-free survival (EFS) of the 20 patients with the CBFA2T3-GLIS2 
fusion gene was significantly worse than that of the 217 pediatric CN-AML patients not 
harboring the translocation (27.4%, standard error [SE] 10.5 vs 59.6%, SE 3.6; P 5 .01; Figure 
14C). We also stratified the patients with respect to FAB subgroups (M7 vs non-M7; Figure 
14D). The 5- year EFS of FAB M7 patients with or without the CBFA2T3-GLIS2 fusion gene 
was significantly different: 26.6% (SE 15.0) and 60.7% (SE 8.3; P5.04), respectively. Similar 
results were obtained in non-M7 patients; the 5-year EFS of patients assigned to other FAB 
categories with or without the CBFA2T3-GLIS2 fusion transcript was 30.0% (SE 14.4) and 
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59.4% (SE 3.5; P 5 .04), respectively. No statistically significant difference in EFS of non-M7 
and M7 patients harboring the CBFA2T3-GLIS2 fusion transcript (30.0%, SE 14.4 vs 26.6%, SE 
15.0; P 5 .91) was found, suggesting that FAB classification does not interact with the 
CBFA2T3-GLIS2 fusion product in influencing outcome. Taken together, these data indicate that 
the CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric CN-AML that is 
not restricted to the FAB M7 subtype, predicting poor outcome. 
3.3 Identification of a novel DHH-RHEBL1 fusion transcript 
in pediatric CBFA2T3-GLIS2-positive AML patients 
Despite the evidence that, in human AML, presence of CBFA2T3-GLIS2 fusion predicts for a 
poor outcome, experimental evidence demonstrated that expression of this chimeric mRNA in 
mice is not sufficient to promote leukemogenesis, suggesting that the fusion protein per se may 
not be sufficient to promote leukemogenesis71,83. Starting from this observation, we reasoned that 
additional lesions can concur to leukemia development in children harboring CBFA2T3-GLIS2 
fusion transcript. Interestingly, further analysis on RNA-seq data revealed the presence of a 
novel fusion transcript in the CBFA2T3-GLIS2-positive patients (2 out of 3 CBFA2T3-GLIS2-
positive patients initially identified by RNA-seq). In detail, this novel fusion transcript is the 
result of a read-through that combines at least part of one exon with each of two distinct (parent) 
genes that are adjacent on the same chromosome in the same orientation84. This transcript 
involves DHH, a member of the Hedgehog family,85 and RHEBL1, a gene coding for a small 
GTPase of the Ras family. Both genes are contiguously localized on the reverse strand of 
chromosome 12 (Figure 15) and, although the mechanism that leads to generation of read-
through fusion transcripts remains so far is obscure,86 RT-PCR analysis and Sanger sequencing 
confirmed that all positive cases harbored the in-frame fusion between exon 2 of DHH and exon 
2 of RHEBL1 (Figure 15). Interestingly, both DHH and RHEBL1 genes have been implicated in 
a variety of human diseases as well as cancer. DHH codes for a member of the Hedgehog (HH) 
signaling pathway, which, similar to other HH ligands, binds to its receptor Patched and leads to 
the signaling cascade of repressive interactions, culminating into effects on the transcription of 
target genes. The HH signaling, during embryogenesis, controls cell proliferation, differentiation 
and tissue morphogenesis87. However, it is also well known to have a role in tumors, and the role 
that HH signaling plays in the growth of tumors can be classified according to how the pathway 
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is activated88. These mechanisms include loss-of-function mutations in inhibitory proteins, such 
as Patched (PTC1), gain-of-function mutations in positive regulators, such as Smoothened 
(SMO), and overexpression of the HH ligands (Sonic, Indian and Desert Hedgehog), leading to 
either autocrine or paracrine activation of the pathway and renewal/propagation of cancer stem 
cells87. RHEBL1 protein belongs to the Ras family of small GTPases and, similar to other Ras 
proteins, is a molecular switch that controls a wide variety of cellular functions including cell 
growth, differentiation and transformation89. Previous studies reported that RHEBL1 could 
function as an activator of NF-kB89 and mTOR90 signaling, both of which are frequently altered 
in many solid tumors, as well as in leukemias and lymphomas82,91–93.  
3.3.1 DHH-RHEBL1 fusion transcript is recurrent in pediatric 
CBFA2T3-GLIS2-positive AML 
To assess the prevalence of DHH-RHEBL1 fusion in pediatric AML, we then examined a 
validation cohort of 55 children with AML. The validation cohort included CN-AML patients 
(N=24), CBFA2T3-GLIS2-positive patients (N=16), patients harboring known 
cytogenetic/genetic abnormalities (alteration of MLL, NPM1, FLT3, t(8;22)(p11;q13), 
t(9;11)(p22;q23), inv(16) (p13;q22)) (N=12) and normal CD34+ hematopoietic stem cells (N=3). 
The DHH-RHEBL1 fusion transcript was detected in 6 out of 16 patients carrying the CBFA2T3- 
GLIS2 fusion, while it was never found in the other patients with AML, irrespectively of the 
mutational status, as well as in normal CD34+ cells. Thus, considering also the patients of the 
sequencing cohort, the DHH-RHEBL1 fusion was globally present in 8 out of 20 (40%) of the 
CBFA2T3-GLIS2-positive patients, this demonstrating that this novel alteration is a common 
feature of this peculiar subset of childhood AML. 
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Figure 15. DHH-RHEBL1 is a novel fusion transcript recurrent in pediatric CBFA2T3-GLIS2 
positive AML. Schematic representation of the fusion between DHH and RHEBL1 identified by means of 
whole-transcriptome sequencing. The figure shows the position of DHH and RHEBL1 on chromosome 12 
and the fusion transcript detected by RNA-seq. The identification of this novel fusion transcript was 
supported by an average of 11 span and 21 split reads. Sanger sequencing performed in order to validate 
the detection of the DHH-RHEBL1 fusion transcript. Electropherogram and predicted sequence of the 
fusion protein are shown. From Masetti R, Togni M, Astolfi A, Pigazzi M, Manara E, Indio V, Rizzari 
C, Rutella S, Basso G, Pession A and Locatelli F. Oncotarget. 2013 Oct;4(10):1712-20. 
Figure 16. Implications of DHH-RHEBL1 fusion transcript expression. (A) Expression levels of 
DHH and RHEBL1 gene obtained from RNA-seq data in DHH-RHEBL1 positive patients (N=2), in 
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CBFA2T3-GLIS2 positive patients (N=2) and in CN-AML patients (N=4). Abbreviations: CPM = count 
per million, Pos = positive. (B) Probability of 8-year overall survival (OS) in CBFA2T3-GLIS2- positive 
children who did or did not harbor the DHH-RHEBL1 fusion transcript (25%, SE=15 vs 55%, SE=15) 
(P=0.1). From Masetti R, Togni M, Astolfi A, Pigazzi M, Manara E, Indio V, Rizzari C, Rutella S, 
Basso G, Pession A and Locatelli F. Oncotarget. 2013 Oct;4(10):1712-20. 
 
3.3.2 DHH-RHEBL1–positive patients exhibit a specific gene 
expression signature and an overexpression of both DHH and 
RHEBL1 
To define the implications, if any, of DHH-RHEBL1 fusion transcript expression, we performed 
a gene expression analysis on RNA-seq data. Firstly, we analyzed the expression level of the two 
genes involved in the fusion transcript and we found that the expression of both DHH and 
RHEBL1 is significantly enhanced in the DHH-RHEBL1-positive patients as compared with 
patients harboring only CBFA2T3-GLIS2 fusion (P=0.007 and P=0.009 respectively) and with 
the other CN-AML cases (P=0.0005 and P=0.043, respectively) (Figure 16A). Recently, with the 
identification of CBFA2T3-GLIS2 fusion transcript in pediatric CN-AML, different studies71,82,83 
demonstrated that the presence of this fusion transcript leads to an aberrant activation of the HH 
signaling due to the ectopic expression of the GLIS2 transcription factor. Notably, here, we 
demonstrate that patients harboring the DHH-RHEBL1 fusion present an overexpression of DHH 
compared to both CBFA2T3-GLIS2-positive patients and CN-AML patients. Considering that 
overexpression of the HH ligands leads to activation of the HH pathway87, it is tempting to 
speculate that overexpression of DHH could contribute to the aberrant activation of the HH 
pathway. Moreover, in view of RHEBL1 over-expression in patients harboring the DHH-
RHEBL1 fusion transcript compared to those harboring only the CBFA2T3-GLIS2 fusion 
transcript and to CN- AML children, it will be interesting to investigate more thoroughly its 
possible role in leukemogenesis. Additionally, DHH-RHEBL1-positive patients showed a 
distinctive gene expression signature both with respect to CBFA2T3-GLIS2-positive patients 
(518 differentially expressed genes; P<0.05), and CN-AML patients (596 differentially expressed  
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Figure 17. Analysis of gene expression profile of DHH-RHEBL1-positive patients. Heatmap of the 
top 30 differentially expressed genes in DHH-RHEBL1-positive patients compared with the patients 
harboring the CBFA2T3-GLIS2 fusion only and CN- AML patients. (A) Gene expression signature of 
patients harboring both CBFA2T3-GLIS2 and DHH-RHEBL1 fusion transcript; (B) Gene expression 
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signature of CBFA2T3-GLIS2-positive patients; (C) Gene expression signature of children with CN-AML 
not harboring any detectable fusion transcript. Abbreviation: Pos = positive. From Masetti R, Togni M, 
Astolfi A, Pigazzi M, Manara E, Indio V, Rizzari C, Rutella S, Basso G, Pession A and Locatelli F. 
Oncotarget. 2013 Oct;4(10):1712-20. 
genes; P<0.05). Interestingly, DHH-RHEBL1-positive patients showed higher expression of 
several genes known to be associated with leukemia occurrence and/or tumor progression, such 
as FLT3,94 BEX1,95 MUC496 and AFAP1L297 (Figure 17). Finally, we also evaluated whether the 
presence of DHH-RHEBL1 fusion transcript influences the outcome of CBFA2T3-GLIS2-
positive patients. The 8-year overall survival of the 8 patients harboring the DHH-RHEBL1 
fusion transcript was worse than that of the 12 CBFA2T3-GLIS2-rearranged patients not 
harboring the DHH-RHEBL1 fusion transcript (25% vs 55%). However, likely due to the small 
number of patients, this difference failed to achieve statistical significance (P=0.1) (Figure 16B). 
3.4 Identification of RUNX1-USP42 and PRDM16-SKI fusion 
transcripts 
Among the CN-AML pediatric patients analyzed by the means of RNA-seq, an 8-year-old child 
diagnosed with AML French-American-British (FAB) type M5b showed an abnormal karyotype, 
46, XY, del(5)(q14q34) with no recurrent genetic abnormality involving MLL, CBFB, NPM1 and 
FLT3 genes. However, due to the rarity of this particular alteration [del(5)(q14q34)] in de novo 
pediatric AML, and its association with a grim survival, the patient was included in the study 
cohort. Interestingly, giving value to the concordant results emerging from the use of three 
distinct algorithms, (Defuse,74 ChimeraScan,75 and FusionMap,76) two fusion transcripts, 
RUNX1- USP42 and PRDM16-SKI, were identified in this patient. Perusal of the reads mapping 
these chimeric transcripts showed that the first was an in-frame fusion, while PRDM16- SKI was 
a novel out-of-frame fusion (Figure 18A). RT-PCR analysis and Sanger sequencing confirmed 
the presence of both chimeric transcripts (Figure 18B). To date, the cryptic t(7;21) leading to the 
fusion between RUNX1 and USP42 has been reported only once in children,98 while seven adult 
cases with myeloid neoplasms harbouring the RUNX1-USP42 transcript have been published 
(Table 8), suggesting that this genetic abnormality is a rare, but non-random, feature of myeloid 
malignancies in adults. To assess the recurrence of RUNX1-USP42 fusion transcript in childhood  
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Figure 18. RUNX1-USP42 and PRDM16-SKI fusion identified through RNA-seq in a child with 
acute myeloid leukaemia (AML) and del(5q). (A) Schematic representation of split read mapping the 
(Figure 18 legend continued…) RUNX1-USP42 and PRDM16-SKI fusions obtained by whole- 
44 
 
transcriptome sequencing (WTS). Defuse, Chimerascan, and FusionMap packages were used to detect 
chimeric transcripts from RNA-seq data. Predicted sequences of the chimeric proteins are reported. (B) 
Reverse transcription polymerase chain reaction (RT-PCR) analysis and Sanger sequencing were 
performed in order to validate the detection of RUNX1-USP42 and PRDM16-SKI fusions. Neg = 
negative. (C) Quantitative RT-PCR (qRT-PCR) analysis was performed in order to detect differential 
expression of the USP42 gene. As a result of the t(7;21) translocation, USP42 gene is placed under the 
control of the RUNX1 promoter, and this could lead to over-expression of the rearranged USP42 gene. To 
test this possibility, we designed a q-PCR with two different primer pairs (wild-type [wt]: primers 
mapping in exons 2–3of USP42; and wt+fusion [fus]: primers mapping in exons 7–8 of USP42) and we 
evaluated the expression of the wt and the wt+rearranged USP42 in 4 cytogenetically normal AML (CN-
AML) samples (CN21, CN23, CN24, CN25), the t(7;21)(p22; q22) positive case (AML74) and in CD34+ 
haematopoietic stem cells. (D) Expression levels of USP42 obtained from WTS data, in the t(7;21) 
(p22;q22) positive patient (AML74), and 7 CN-AML patients (CN21, CN22, CN23, CN24, CN25, CN65, 
CN68). CPM = count per million. (E) q-PCR analysis was performed in order to detect differential 
expression of the PRDM16 gene in the t(7;21)(p22;q22) positive case (AML74), and in five paediatric 
CN-AML samples (CN21, CN23, CN25, CN65, CN68). (F) Expression levels of PRDM16 obtained from 
WTS data in the t(7;21)(p22;q22) positive patient (AML74), and 7 CN-AML patients (CN21, CN22, 
CN23, CN24, CN25, CN65, CN68). AML74 is in this study CN-AML#14, CN21 is in this study CN-
AML#5, CN22 is in this study CN-AML#6, CN23 is in this study CN-AML#7, CN24 is in this study CN-
AML#9, CN25 is in this study CN-AML#10, CN65 is in this study CN-AML#11, CN68 is in this study 
CN-AML#12. From Masetti R, Togni M, Astolfi A, Pigazzi M, Indio V, Rivalta B, Manara E, Rutella S, 
Basso G, Pession A, Locatelli F. Br J Haematol. 2014 Aug;166(3):449-52. 
AML, we examined 132 children with de novo CN-AML enrolled in the AIEOP AML 2002/01 
Protocol. No additional patient was found to carry this chimeric transcript. To the best of our 
knowledge, this is the second paediatric case in which the RUNX1-USP42 fusion transcript has 
been detected and, unprecedentedly, it was observed at diagnosis together with del(5q), whereas 
in the case described by Paulsson et al (2006) the 5q- occurred later in the disease course.98 In 
our case, the fusion occurred between exon 6 of RUNX1 and exon 3 of USP42 (Figure 18A-B). 
However, as previously reported, owing to different breakpoints and alternative splicing in 
RUNX1, several splice-variants of RUNX1-USP42 chimeric transcript may be generated by the 
cryptic t(7;21) (Table 8) 99. Noteworthy, all RUNX1-USP42 isoforms harbour both the catalytic 
domain (UCH) of USP42 and the highly conserved Runt homology domain (RHD) of RUNX1, 
which mediates DNA binding and heterodimerization of RUNX1 with CBFb. Several 
mechanisms through which this chimeric transcript could contribute to the leukaemogenesis have 
been proposed: (i) dominant negative inhibition of wild-type RUNX1 transcription activation 
activity98,100 (ii) USP42-mediated stabilization of RUNX1 from ubiquitin-proteasome 
degradation,98 and iii) ectopic over-expression of USP42 and deregulation of TP53-dependent 
cell-cycle arrest101. In accordance with the last hypothesis, through q-PCR analysis, we 
demonstrated an over-expression of USP42 in t(7;21)-positive cells when compared with other 
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CN-AML cells lacking this translocation, and CD34+ haematopoietic progenitors (P = 0.02) 
(Figure 18C). This finding was further validated through gene expression analysis performed on 
the RNA-seq data (Figure 18D). Taken together, these results confirm and extend previous 
reports,100 enforcing the potential role of this proteinase in leukaemogenesis, and lending support 
to both the role of deubiquitinating proteins in tumourigenesis and the use of deubiquitinating 
enzyme inhibitors in cancer therapy. Despite this finding, animal models have shown that 
RUNX1-related translocations or haploinsufficiency of RUNX1 are not sufficient for 
leukaemogenesis, indicating that additional genetic events are required. Interestingly, whole-
transcriptome sequencing enabled the identification of a novel out-of-frame fusion transcript in 
which exon 1 of PRDM16 (also known as MEL1) is fused with exon 2 of SKI (v-ski avian 
sarcoma viral oncogene homolog). Due to loss of the open-reading frame, no putative chimeric 
protein seems to be encoded by this fusion transcript. However, considering the relative position 
of the two genes on the forward strand of chromosome 1, we speculate that the juxtaposition of 
SKI downstream of exon 1 of PRDM16 may lead to slipping of PRDM16 and this, in turn, 
positions the gene under the control of ectopic promoter/enhancer elements (Figure 18A-B). To 
test this hypothesis, we evaluated the expression levels of PRDM16 by q-PCR and gene 
expression analysis on RNA-seq data, and found that its expression was significantly enhanced 
in the t(7;21)-positive patient compared to other CN-AML patients (P = 0.01) (Figure 18E-F). 
Additionally, SKI expression was investigated through both q-PCR and RNA-seq gene 
expression analysis. However, no differential expression of this gene was detected (data not 
shown). Coding for a zinc-finger protein containing a DNA-binding PRDI-BF1/RIZ homologous 
(PR) domain, PRDM16 belongs to the EVI1 family, and is implicated in two translocations 
involving RUNX1 and RPN1 in myeloid malignancies. Interestingly, several reports indicate the 
link between overexpression of PRDM16 and leukaemogenesis, strengthening its association 
with a worse outcome102,103. In summary, we reported, for the first time, the identification of a 
RUNX1-USP42 fusion transcript detected at diagnosis in a child with AML and del(5). No other 
child was positive for this chimeric transcript in a lager validation cohort, demonstrating that this 
is a rare genetic lesion in childhood AML. Interestingly, RNA-seq also enabled the identification 
of a novel out-of-frame PRDM16-SKI fusion, and analysis of PRDM16 revealed an 
overexpression of this gene.  Notably, an additional CN-AML patient of our sequencing cohort 
was found to be positive for the out-of-frame PRDM16-SKI fusion and, preliminary results form 
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a screening in 230 children with newly diagnosed de novo CN-AML indicate both a considerable 
incidence of this genomic alteration in this subgroup of childhood leukemias and a consequent 
overexpression of PRDM16 gene (data not show). 
 
Table 8. Main characteristics of t(7;21)(p22; q22) positive patients 
N Age, years 
Gender 
(M/F) Disease 
WBC
, 
x109/
L 
BM blast 
percentage 
at diagnosis 
del(5q) 
at 
diagnosis 
Fusion 
(isoform) 
HSCT 
(type) Relapse Ref 
1 7 Male AML M0 35.6 75-80% No RUNX1ex7(iso2)-USP42ex3(iso1) 
Yes 
(SIB) Yes 
98 
2 68 Female MDS (RAEB-2) NA 17% No 
RUNX1ex6(iso2) 
-USP42ex3(iso1) No No 
99 
3 68 Male AML M5 NA NA No RUNX1ex7(iso2) -USP42ex3(iso1) No No 
99 
4 32 Male AML M1 12.1 90% Yes RUNX1ex7(iso2) -USP42ex3(iso1) NA NA 
101 
5 54 Male AML M4/M5 17.6 73% Yes 
RUNX1ex7(iso2) 
-USP42ex3(iso1) 
Yes 
(NA) Yes 
104 
6 33 Male AML M5a 5.4 84% Yes RUNX1ex7(iso2) -USP42ex3(iso1) 
Yes 
(SIB) No 
104 
7 39 Male AML M4/M5 1.3 NA Yes 
RUNX1ex6(iso2) 
-USP42ex3(iso1) No NA 
104 
8 52 Female AML M0 34 >70% Yes RUNX1ex7(iso2) -USP42ex3(iso1) 
Yes 
(SIB) No 
100 
9 8 Male AML M5 96.18 60% Yes RUNX1ex6(iso2) -USP42ex3(iso1) 
Yes 
(MUD) No 
Present 
Case 
Sib = sibling; MUD = matched unrelated donor. NA= not available. From Masetti R, Togni M, Astolfi A, 
Pigazzi M, Indio V, Rivalta B, Manara E, Rutella S, Basso G, Pession A, Locatelli F. Br J Haematol. 2014 
Aug;166(3):449-52. 
 
 
3.5 NUP98-PHF23 is a recurrent fusion gene in pediatric 
CN-AML 
RNA-seq performed on diagnostic leukemic cells was also able to reveal in 2 out of 19 analyzed 
patients a fusion involving the genes NUP98 and PHF23, resulting from a cryptic translocation 
t(11;17)(p15;p13) (Figure 19A) (Table 9). Both patients showed an in-frame fusion between 
exon 13 of NUP98 and exon 4 of PHF23 and RT-PCR analysis and Sanger sequencing 
confirmed the fusion breakpoint (Figure 19B). To date, the identification of the cryptic 
translocation t(11;17)(p15;p13) has been described only once in an adult AML patient105 and, to 
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our knowledge, this feature has never been reported in a pediatric AML cohort. In addition, 
differently from what previously reported by Reader and colleagues,105 here the recurrent 
breakpoint in PHF23 gene was in both cases identified at the start of exon 4 and not within it 
(Figure 17A-B). This finding indicates that NUP98-PHF23 fusion gene can involve either the 
whole exon 4 of PHF23 or only a fragment of it. To investigate the incidence of NUP98-PHF23 
fusion in pediatric CN-AML, we examined through RT-PCR analysis and Sanger sequencing a 
validation cohort of 152 AML children enrolled in the AIEOP AML 2002/01 Protocol (Pession, 
et al 2013): 135 patients were negative for the recurrent cytogenetic lesions or genetic 
abnormalities, involving MLL, CBFB, NPM1 and FLT3, while the remaining 17 patients 
harbored FLT3-ITD mutation, and were chosen because we previously reported a strong 
association between NUP98-NSD1 rearrangement and FLT3-ITD106. Overall, 2 out of 152 CN-
AML patients were positive for the NUP98-PHF23 fusion, demonstrating that this genomic 
aberrancy is not rare in pediatric CN-AML (Table 9). The presence of the cryptic chromosomal 
translocation t(7;11)(p15;p13), leading to the fusion between NUP98 and PHF23 genes was 
confirmed by fluorescence in situ hybridization (FISH) analysis in all cases (Figure 19C). 
Located on 11p15.5, NUP98 encodes a 98-kD protein component of the nuclear pore complex, 
which facilitates mRNA export from the nucleus. So far many chromosomal rearrangements 
involving NUP98 have been described to be associated with both de novo and therapy-related 
AML, but also with T-cell acute lymphoblastic leukemia (T-ALL). At present, more than 15 
different partner genes have been found rearranged with NUP98107. Known fusion partners can 
be divided into three groups: homeobox (HOX) genes (HOXA9, HOXA11, HOXA13, HOXC11, 
HOXC13, HOXD11 and HOXD13), nuclear non-homeotic genes (LEDGF, NSD1, NSD3, 
DDX10, TOP1, TOP2B, FN1 and C6orf80) and two genes found exclusively fused with NUP98 
in T-ALLs (RAP1GDS1 and ADD3). In childhood AML, recently, a novel fusion transcript 
involving NUP98, namely NUP98/JARID1A has been described to be a recurrent event in 
approximately 11% of pediatric patients with acute megakaryoblastic leukemia, with a distinct 
HOX gene expression pattern108. By contrast, chromosomal rearrangements and/or mutations of 
PHF23 were never before described in children with AML. Located on the reverse strand of 
17p13.1, PHF23 gene encodes for a protein containing a plant homeodomain (PHD) finger109. 
PHD zinc fingers are structurally conserved motifs found in several nuclear proteins thought to 
be involved in epigenetic and chromatin-mediated transcriptional regulation. 
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Figure 19. Identification of NUP98-PHF23 in pediatric CN-AML. (A) Schematic 
representation of NUP98-PHF23 fusion identified by RNA-seq in pediatric CN-AML. Fusion 
occurs between exon 13 of NUP98 and exon 4 of PHF23. (B) Electropherogram from Sanger 
sequencing of the region surrounding the breakpoint confirmed the in frame fusion. Black arrow 
indicate the fusion breakpoint, predicted sequence of the fusion protein is showed. (C) FISH 
analysis was performed on metaphases and interphase cells using three BlueFISH probes 
(BlueGnome Ltd., Cambridge), according to manufacturer’s instructions. BAC clones RP11-
120E20 and RP11-348A20 (red) were used to probe the NUP98 gene on chromosomes 11, while 
the BAC clone RP11-542C16 (green) was used to target the PHF23 gene on chromosome 17. 
Normal metaphases (up left) and interphase nuclei (up right) showed two red signals 
representing normal copies of NUP98 and two green signals representing normal copies of 
PHF23. Abnormal metaphases (down left) and interphase cells (down right) containing the 
NUP98-PHF23 fusion gene showed one red (NUP98), one green (PHF23) and one yellow fusion 
signal which represents the juxtaposition of the translocated portions of the two genes. 
 
Recent studies showed that these domains have a sophisticated histone sequence reading 
capacity, underscoring the functional versatility of PHD fingers as epigenome readers that 
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control gene expression through molecular recruitment of multi-protein complexes of chromatin 
regulators and transcription factors105. 
Table 9. Clinical features of pediatric CN-AML patients harboring the NUP98-PHF23 fusion gene 
Id 
Age, 
(y) 
Gende
r 
WBC, 
x 
109/L 
FAB 
BM 
(%) 
ED 
HSCT 
(type) 
CR 
after 
inductio
n 
therapy 
Relaps
e (site) 
DFD 
(m) 
Sur (m) 
CN-AML_54* 2.9 M 187 M1 90 No  AUTO Yes (BM) 5 † 30 
CN-AML_66* 9.0 M 1.2 M0 70 No  MUD Yes - 65 66 
AML_3 9.7 M 6.9 M4 40 No  MUD Yes - 40 41 
AML_4 7.0 M 1.8 M5A 54 No  AUTO Yes - 103 104 
*, patients identified by RNA-seq; †, dead patients; AUTO, autologous; CR, complete remission; HSCT, 
hematopoietic stem cell transplantation; MUD, matched unrelated donor; WBC, white blood cells. y, years; BM, bone 
marrow blast % at diagnosis; EM, extramedullary involvement DFD, disease-free duration; Sur, survival duration: m, 
months. CN-AML_54* is in this study CN-AML#13, CN-AML_66* is in this study CN-AML#18. 
 
The role of NUP98-PHF23 in leukemogenesis has investigated by functional studies showing 
that the expression of this fusion protein impaired the differentiation of myeloid progenitor cells 
and is sufficient to promote leukemia development in vitro and in vivo105,109,110. Noteworthy, 
cells expressing NUP98-PHF23 are sensitive to low concentration of disulfiram, a U.S. Food and 
Drug Administration–approved drug, demonstrating the feasibility of targeting this oncoprotein 
as well as other PHD fusion proteins like NUP98-JARID1A110. In summary, here we reported 
the identification of a NUP98-PHF23 chimeric transcript in a pediatric acute myeloid leukemia 
cohort, demonstrating that this genomic aberrancy is not rare (2.4%) in pediatric CN-AML. 
Taken together these findings strengthen the importance role of genes coding for epigenetic 
regulators in pediatric AML and suggest thethe putative use of novel epigenome-targeted 
therapies in this pathological setting. 
3.6 Identification of TNIP1-PDGFRB fusion transcript in 
children with CN-AML 
Although its presence was detected only in 1 out of 19 analyzed patients (5%), the identification 
of the in-frame  TNIP1-PDGFRB fusion has been selected for further analyses due to the well-
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known role in cancer of the platelet-derived growth factor receptor β (PDGFRB) gene.111 
Constitutive activation of the PDGFRB receptor tyrosine kinase has been reported in myeloid 
malignancies as a consequence of fusion to diverse partner genes (Table 10). PDGFRB 
overexpression is implicated in the pathogenesis of dermatofibrosarcoma protruberans (DFSP) 
and overexpression of PDGFRs and/or their ligands has been described in many solid 
neoplasms112. Furthermore, and more important, PDGFRB signaling is selectively inhibited by 
imatinib and other tyrosine kinase inhibitors (TKIs) already approved by FDA, and these 
selective drugs have been extensively used in several pathological settings in which PDGFR 
abnormalities have been implicated. Recently, analyzing a cohort of 15 BCR-ABL1-like acute 
lymphoblastic leukemia (Ph-like ALL) patients by RNA-seq and whole-genome sequencing, the 
laboratory leaded by Charles Mullighan showed that genetic alterations activating kinase or 
cytokine receptor signaling are a hallmark of this subtype of pediatric B-ALL, which lacks 
recurrent genetic alterations. Particularly, a novel gene fusion involving the early B-cell factor 1 
(EBF1) gene and PDGFRB gene has been reported and a screening in an independent cohort of 
231 high-risk B-progenitor ALL cases revealed the recurrence of this novel fusion gene in Ph-
like ALL (up to 8%)113. Additionally, the effective clinical use of imatinib has been recently 
reported in two pediatric patients with EBF1-PDGFRB–positive B-ALL, demonstrating that 
TKIs treatment could be successfully used in this pathological setting114,115. By the means of 
RNA-seq, additional PDGFRB-fusions have been identified by our group and others in pediatric 
B-ALL. Particularly, Kobayashi K and collaborators have recently reported a novel ATF7IP-
PDGFRB fusion in a 8-year-old boy with standard-risk B-ALL,116 and Charles Mullighan’s 
group have recently identified ZEB2 and TNIP1 genes as novel partner genes of PDGFRB in Ph-
like ALL113. Interestingly, here I report the identification of  TNIP1-PDGFRB fusion also in one 
patient of our CN-AML cohort, suggesting that this type of gene fusion could be a very early 
genetic alteration that occurs in the hematopoietic precursors before their commitment in the 
lymphoid or myeloid lineage. Specifically, the RNA-seq revealed an in-frame fusion involving 
the exon 17 of TNIP1 gene and the exon 11 od PDGFRB gene leading to the generation of a 
chimeric protein in with both the dimerization domain of TNIP1 and the tyrosine-kinase domain 
of PDGFRB are maintained. Likewise the other PDGFRB-fusions, the suppose mechanism 
leading to the constitutive activation of this chimeric kinase is mediated by an increased ability 
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of the fusion protein to made dimer or oligomer, constitutively allowing the cross-activation of 
the tyrosine-kinase domain of PDGFRB (Figure 20). 
Table 10. PDGFRB-fusions so far reported in myeloid malignancies 
5’ Gene Partner Chromosomal rearrangement Disease Oligodimerization Domain Ref 
ETV6/TEL t(5;12)(q33;p13) CMML SAM Pointed Domain # 117 
CEV14/TRIP11 t(5;14)(q33;q32) AML Coiled Coil 118 
HIP1 t(5;7)(q33;q11.2) CMML Coiled Coil 119 
CCDC6/H4 t(5;10)(q33;q21) MDS Coiled Coil 120 
RABAPTIN5 t(5;17)(q33;p13) CMML Coiled Coil 121 
PDE4DIP/myomegalin t(1;5)(q23;q33) MDS Coiled Coil 122 
TP53BP1 t(5;15)(q33;q22) MPN NA 123 
NIN t(5;14)(q33;q24) MPN Coiled Coil 124 
HCMOGT-1/CYTSB t(5;17)(q33;p11.2) JMML Coiled Coil 125 
KIAA1509/CCDC88C t(5;14)(q31;q32) MDS Coiled Coil 126 
TROPOMYOSIN TPM3 t(1;5)(q21;q33) CEL Coiled Coil 127 
NDE1 t(5;16)(q33;p13) CMML Coiled Coil 128 
GIT2 t(5;12)(q31-33;q24) MDS Ankyrin Repeat 129 
GPIAP1/CAPRIN1 t(1;5;11) CEL Coiled Coil 129 
PRKG2 t(4;5;5)(q23;q31;q33) MPN Coiled Coil # 129,130 
ERC1 t(5;12)(q33;p13.3) AML Coiled Coil 131 
SPTBN1 t(2;5)(p21;q33) MPN NA 130 
Myosine/MYO18A t(5;17)(q33-34;q11.2) MPN Coiled Coil 132 
SART3 t(5;12)(q31–32;q23–24) MPN Coiled Coil 
133 
WDR48 t(5;3)(q33;p21) MPN NA 134 
GOLGA4 t(5;3)(q33;p21) MPN Coiled Coil 134 
BIN2 t(5;12)(q33;q13) MPN Coiled Coil 134 
KANK1 t(5;9)(q32;p24) Throm Coiled Coil 135 
EBF1 Del5(q33q33) Ph-like ALL Coiled Coil 136 
CEP85L t(5;6)(q33-34;q23) T-ALL* -MPN Coiled Coil 137,138 
ATF7IP t(5;12)(q33;p13.1) Ph-like ALL *Coiled Coil 116 
DTD1 t(5;20)(q33;p11) EosM/LN Not present 139 
CCDC88C t(5;14)(q33;q32) EosM/LN Coiled Coil 139 
TNIP1 Del5 Ph-like ALL Coiled Coil 113 
ZEB2 t(5;2)(q33;q22.3) Ph-like ALL NA 113 
CMML, Chronic Myelomonocytic Leukemia; AML, Acute Myeloid Leukemia; MDS, Myelodysplastic Syndromes; 
MPN, Myeloproliferative Neoplasms; JMML, Juvenile Myelomonocytic Leukemia; CEL, Chronic Eosinophilic 
Leukemia; CMML, Chronic Myelomonocytic Leukemia;Throm, Thrombocythemia; Ph-like ALL, Ph-like Acute 
Lymphoblastic Leukemia; T-ALL, Precursor T Lymphoblastic Leukemia; EosM/LN, Eosinophilia-Associated 
Myeloid/Lymphoid Neoplasms; NA, not avaible. 
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3.6.1 TNIP1-PDGFRB sustains cytokine-independent growth in-
vitro 
To evaluate the transforming potential of TNIP1-PDGFRB in-vitro, we assessed the ability of 
murine interleukin-3 (IL-3)-dependent mouse hematopoietic Ba/F3 expressing TNIP1-PDGFRB 
to proliferate in the absence of exogenous cytokines. 
 
 
Figure 20. Identification of TNIP1-PDGFRB in pediatric CN-AML. Schematic representation of the 
two proteins and Sanger validation of the fusion breakpoint, confirming the juxtaposition of exon 11 of 
PDGRFB downstream the exon 17 of TNIP1. 
 
As shown in Figure 21, preliminary data indicated that the expression of TNIP1-PDGFRB 
confers growth factor independence, suggesting that this chimeric protein could sustain an 
uncontrolled proliferation and could be important into leukemogenesis. 
3.6.2 Ba/F3 cells expressing TNIP1-PDGFRB are sensitive to 
treatment with TKIs 
Finally, the potential effect of several FDA-approved TKIs was investigated. Ba/F3 cells 
expressing TNIP1-PDGFRB were treated for 72h with increasing concentrations of imatinib, 
dasatinib and crenolanib (ABL1-kinase class inhibitors), and then analyzed using CellTiter-
Blue® Cell Viability Assay. Noteworthy, all the drugs used showed a strong ability to inhibit the 
cytokine-independent proliferation as indicate in Figure 22 
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Figure 21. TNIP1-PDGFRB sustains cytokine-independent growth in-vitro. Mouse hematopoietic 
Ba/F3 cells were transduced with retroviral vector carrying MSCV-TNIP1-PDGFRB-IRES-GFP (blue 
curve) or MSCV-IRES-GFP (empty vector control) (gray curve) using RetroNectin (Takara Bio)-coated 
plates. After 3 days, cells were harvested and sorted by flow-cytometry for GPF expression. The 
expression of the fusion gene was checked at mRNA and protein level by RT-PCR/Sanger sequencing 
and western blot, respectively. To evaluate factor-independent growth, cells were washed three times with 
PBS 1X, and then seeded in triplicate at the concentration of 0.2M cells/well in 24-wells plate with 
(dotted-line) or without cytokine (solid-line). Cell proliferation and viability will be assessed every two 
days for a total of 12 days by trypan blue count using TC20™ Automated Cell Counter (Biorad). B3, 
Ba/F3 cells. Error bars represent mean ±SD of three independent experiments. 
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Figure 22. Ba/F3 cells expressing TNIP1-PDGFRB are sensitive to treatment with TKIs. 72h 
treatment with TKIs in Ba/F3 cells expressing TNIP1-PDGFRB with (dotted-line) or without (solid-line) 
IL-3. B3, Ba/F3 cells. No cytotoxic effects were observed with cells maintained in factor indicating that 
imatinib specifically targets the activated PDGFRB and ABL1 kinases. Error bars represent mean ±SD of 
three independent experiments. 
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CHAPTER IV – Conclusions and 
future directions 
 
Pediatric CN-AML patients have always showed a great variability in response to therapy and 
overall outcome, underlining the presence of unknown genetic changes, not detectable by 
conventional analyses, but relevant for pathogenesis, dynamics, and outcome of AML. Due to 
the lacking of any prognostic marker, “all-neg” CN-AML patients were historically classified in 
the intermediate-risk class. However, during the last decade, the development of novel genome-
wide techniques such as next-generation sequencing, have tremendously improved our ability to 
interrogate the cancer genome, raising, for the first time, the possibility to have a complete 
picture of all the genetic alterations that could be present in a cancer cell. Along this line of 
research, the overall aim of this study was to investigate the mutational landscape of pediatric 
CN-AML patients negative for all the currently known somatic mutations reported in AML 
through whole-transcriptome sequencing. 
Based on the results here obtained, the first consideration worth to be made is that RNA-seq 
revealed an high incidence of cryptic chromosomal rearrangements that generates fusion genes in 
pediatric CN-AML. Moreover, and more important, several of the fusion genes that were 
identified in this study are recurrent and could have a prognostic and/or therapeutic relevance. A 
paradigm of that is the CBFA2T3-GLIS2 fusion, which has been demonstrate to be a novel 
common (8.4%) alteration in pediatric CN-AML, predicting poor outcome. Noteworthy, due to 
its prognostic relevance, the presence of this fusion gene will be included in the stratification of 
patients in the new AIEOP LAM 2012/01 protocol. Additionally, the identification in about 40% 
of CBFA2T3-GLIS2-positive patients of the DHH-RHEBL1 read-through fusion transcript raise 
the possibility to define another subgroup of CN-AML with a very poor outcome, even if further 
studies are required to better characterized the prognostic significance of this alteration. Moving 
forward, whole-transcriptome sequencing enabled us to identify also a novel out-of-frame fusion 
transcript involving PRDM16 and SKI genes. We demonstrated through q-PCR and gene 
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expression analysis base on RNA-seq data that PRDM16-SKI-positive patients showed a 
significant overexpression of PRDM16 gene, suggesting that the juxtaposition of SKI 
downstream of exon 1 of PRDM16 may lead to slipping of PRDM16 and this, in turn, positions 
the gene under the control of ectopic promoter/enhancer elements. Interestingly, several reports 
indicate the link between overexpression of PRDM16 and leukaemogenesis, strengthening its 
association with a worse outcome. Remarkably, preliminary results form a screening in 230 
children with newly diagnosed de novo pediatric CN-AML indicate both a considerable 
incidence of this genomic alteration in this subgroup of childhood leukemias and a consequent 
overexpression of PRDM16 gene (data not show), paving the way to further analysis of the 
prognostic value of PRDM16-SKI gene in this pathological setting. 
Beyond the role of these fusion genes in defying the outcome of pediatric CN-AML patients, 
important findings have been obtained also regarding the possibility to develop targeted 
treatments against novel molecular alterations. On one side, the identification of NUP98-PHF23 
and NUP98-JARID1A fusions in 2.4% and 1.2% of pediatric CN-AML, respectively, raise the 
possibility to used disulfiram or other small molecules that inhibit the PHD binding to H3K4me3 
also in paediatrics. On the other side, even if its presence was detected only in 1 out of 19 
analyzed patients, the identification of the in-frame TNIP1-PDGFRB fusion is an important 
breakthrough in the use of tyrosine kinase inhibitors in AML. Through cloning and expression of 
TNIP1-PDGFRB  in murine interleukin-3 (IL-3)-dependent mouse hematopoietic Ba/F3, here we 
demonstrated how the expression of this chimeric protein confers growth factor independence, 
suggesting that this chimeric protein have the ability to sustain an uncontrolled proliferation and 
could be important into leukemogenesis. Additionally, we also demonstrated that treatment with 
tyrosine kinase inhibitors blocks the cytokine-independent proliferation of Ba/F3 cells expressing 
TNIP1-PDGFRB and drive them to death. Taken together these data strongly indicate the 
possibility to use these targeted-drugs in TNIP1-PDGFRB-postive CN-AML pediatric patients 
and it is ongoing a screening in an independent and lager cohort of de novo pediatric CN-AML 
with the aim to investigate the recurrence of this alteration. 
Despite the novel cryptic alteration identified so far in this study, several aspects need to be 
evaluated in the future to finally have a complete picture of the mutational landscape of pediatric 
CN-AML. Firstly, RNA-seq allows us to identify not only chromosomal rearrangements leading 
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to fusion genes, but also single-nucleotide-variants (SNVs), and insertion/deletion (InDel). 
However, in order to discriminate which SNVs are specifically present in the leukemic cells 
(somatic mutations), and which are wild-type variations (germ-line mutations) a diagnosis/germ-
line paired analysis is required and the whole-exome sequencing of germ-line sample for the 
cases here analyzed is currently ongoing. Moreover, also the heterogeneity and the clonality of 
leukemic cells is an important aspect that we need to take in account: not all the leukemic cells 
show specific mutations and treatments can be more effective on specific clones rather than 
other. Base on that, the clonal dissection is a crucial to completely define the population of cells 
that could be present in a leukemic sample and it is now ongoing a paired whole-exome 
sequencing (diagnosis/remission/relapse) of three CN-AML pediatric patients of this study 
cohort in order to obtain data on the clonality of the identified mutation. The combination of the 
results here reported and the emerging data that will be obtained in the future by us and other 
important groups or consortia (e.g. TCGA, PCGP) are expected to be crucial to characterize the 
landscape of mutation in pediatric CN-AML, leading, ultimately, to make personalized medicine 
a reality in the near future. 
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